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Abstract
This paper studies the Brazilian psychiatric reform, which reorganized mental health-
care provision by the public system building a network of community-based services
centered on the Psychosocial Care Centers (CAPSs). Our research design exploits the
roll-out of CAPSs in a differences-in-differences framework. We show that these centers
improved outpatient mental healthcare utilization and reduced hospital admissions due
to mental and behavioral disorders. Those reductions were more pronounced for long-
stay admissions and among patients with schizophrenia. Additionally, centers deliver-
ing substance abuse treatment reduced deaths caused by alcoholic liver disease. Finally,
we also find that this shift away from inpatient care increased homicides.
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1 Introduction
Mental and addictive disorders affected more than 1 billion people globally in 2016, being
considered one of the most burdensome non-communicable diseases in the world (Rehm
and Shield, 2019). People with major depression and schizophrenia have a 40% to 60%
greater chance of dying prematurely than general population. Besides that, suicide is the
second most common cause of death among young people worldwide (WHO, 2013). The
absence of mental health may also have devastating effects on an individual’s ability to
lead a balanced professional, social and family life (Roy and Schurer, 2013; Frijters et al.,
2014; Kessler et al., 1998). The economic consequences of these are equally large. Estimates
suggest that the global impact of mental disorders in terms of lost economic output for the
period 2011-2030 will amount US$ 16.3 trillion (Bloom et al., 2012). Yet, health systems
have not adequately responded to the burden of mental health disorders. The gap between
the need for treatment and its provision is large all over the world. In low and middle
income countries, between 76% and 85% of people with severe mental illness do not receive
treatment for their disorder. The corresponding range for high income countries is also high:
between 35% and 50% (WHO, 2013).
The numbers indicate that a better provision of mental health care might significantly
improve a given population’s well-being. It is not obvious, though, how to optimally pro-
vide this type of care. In the second half of the twentieth century, many countries started
to switch from a model of mental health care centered on psychiatric hospitals toward a
model based on community care. However, international experience shows that this pro-
cess is not something simple to be done. Reducing hospital admissions without offering
adequate community-based care with proper integration to other medical services may not
only fail to improve the delivery of mental health care services, but also generate undesir-
able consequences (Sisti et al., 2015; Rosenbaum, 2016; Lamb, 2015).1 Hence, it is important
to understand how different strategies to implement community-based mental health care
work and how deinstitutionalization can be done while avoiding the potential pitfalls asso-
ciated with it.
Despite this significant change in philosophy and its importance, there is little rigor-
ous research measuring the effects of policies directed toward the effective provision of
1This idea is often connected with the concept of transinstitutionalization: when individuals are released
from psychiatric institutions and no adequate option is offered, they may migrate to other institutions, usually
part of the correctional system.
2
community-based mental healthcare. This paper investigates this question by examining the
psychiatric reform in Brazil. The Brazilian reform was centered on the introduction of Psy-
chosocial Care Centers (Centros de Atenção Psicossocial – henceforth, CAPSs) as a community-
based substitute for inpatient care for people with moderate or severe mental disorders.
More specifically, CAPSs provide a number of outpatient procedures such as medical con-
sultations, individual and group therapy, and therapeutic workshops. Also, CAPSs, as part
of the national healthcare system (Sistema Único de Saúde – SUS), work as gateways to the
mental health care system and, if adequate care cannot be provided there, the person can
be referred to the adequate facility. Hence, to study the psychiatric reform, we focus on the
effects of introducing a CAPS in a municipality. In particular, we assess the CAPSs’ effects
on density of mental health professionals, on utilization of outpatient mental healthcare,
and on deaths and hospital admissions by cause. Among causes, we investigate mental and
behavior disorders, suicide, alcoholic liver disease, and overdose.
We additionally study the reform’s effect on homicides. A recurrent concern about dein-
stitutionalization – the process of reducing mental hospitalization and providing community-
based alternative services (Lamb and Bachrach, 2001) – is with increased violence. There is
extensive evidence that severe mental illness is closely associated with an increased risk of
aggressive behavior, crime and victimization (Hodgins et al., 1998; Rueve and Welton, 2008;
Fazel et al., 2009; Teplin et al., 2005). Historically, there has been a debate about criminality
and inpatient versus community-based mental healthcare. For example, in the 70’s, when
community services started to expand in the U.S., people fearing an increase in crime in
their community made so much opposition that several new psychiatric centers had to be
closed (Rabkin, 1979). A few specialists share a similar concern by advocating that com-
munity care is not suited for all mentally ill persons, especially those at risk of becoming
criminalized (Lamb and Weinberger, 2005). Contrary, others defend that this type of care
can be successful in such cases, provided that adequate community treatment resources are
available (Slate et al., 2013). Empirically, this is still an open question.
Our empirical strategy exploits the roll-out of CAPSs across the the Brazilian municipali-
ties in a differences-in-differences framework. Following De Chaisemartin and d’Haultfoeuille
(2020), we use a DID estimator that is robust to heterogeneous treatment effects across co-
horts and over time. Parallel pre-trends for the set of outcomes we evaluate provide evi-
dence on the design validity. To evaluate the policy effects, we use several administrative
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data. These include information on mental health providers, psychiatric beds, outpatient
mental health production, and mortality and hospital admissions by cause. We first docu-
ment that the introduction of CAPSs increased access and utilization of community-based
mental health care. More specifically, the implementation of these centers was associated
with immediate and large increases in the density of mental health professionals, as well as
in outpatient visits made by them. Consistent with these results, we also found an increase
in the number of drugs dispensed in outpatient care for the treatment of psychiatric disor-
ders. Turning to morbidity and mortality outcomes, we find that CAPSs decreased hospital
admissions due to mental illness. The effects are driven by the reduction of long-stay hospi-
talizations of individuals with schizophrenia. Additionally, centers specialized in substance
abuse treatment reduced deaths due to alcoholic cirrhosis. Despite these positive effects, we
also find a modest increase in homicide rates, potentially caused by the CAPSs’ effects on
mental hospital admissions. In particular, we found a relation of 1.7 homicides for each 10
less mental hospitalizations, which is line with the prevalence of violent crimes committed
by former psychiatric in-patients reported by the literature. Heterogeneous effects suggest
that increased victimization is not the main driver producing these results.
This paper contributes to the rich economic literature on mental health. Many papers
study different determinants of mental health, as medication (Dalsgaard et al., 2014; Ludwig
et al., 2009), early life conditions (Persson and Rossin-Slater, 2016; Almond and Mazumder,
2011; Adhvaryu et al., 2019), economic shocks (Ruhm, 2000; Schwandt, 2018), and income
shocks (Christian et al., 2019; Baird et al., 2013). A recent set of experimental papers evalu-
ate the effects of psychological interventions on mental health or related outcomes (Baranov
et al., 2020a,b). Finding evidence of government policies that impact mental health, how-
ever, is a much harder task. A few papers study policies that look at some measure of
mental health as a secondary outcome, like Katz et al. (2001) on the Moving to Opportunity
program or Milligan and Stabile (2011) on child tax benefit expansions. We are not aware,
though, of any paper that studies a large scale public policy targeted specifically at mental
health. This paper helps to fill this gap.
Despite being one of the first studies to study the effects of community-based mental
healthcare, we are well aware that the question of whether this type of care is effective is
not new to the public health and medical literature (Wiley-Exley, 2007). Community-based
mental health services has been linked negatively to mental hospitalizations (Wanchek et al.,
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2011; Madianos and Economou, 1999), suicide rates (Pirkola et al., 2009; While et al., 2012),
and measures capturing symptoms of schizophrenia and bipolar disorders (Chatterjee et al.,
2003; Chisholm et al., 2005; Hickling et al., 2001). However, the existing studies do not
aim a causal interpretation and many of them use very small samples. To the best of our
knowledge, the present study is the first to exploit a quasi-experimental design to investigate
the causal effects of the introduction of community-based mental healthcare in large scale.
As we also evaluate centers providing substance abuse treatment, our findings comple-
ment evidence by Swensen (2015). Using U.S. data, the author conducted the first nation-
wide analysis documenting the causal benefits of substance-abuse treatment on mortality. In
particular, drug-overdose deaths. Differently, we present evidence for a developing country
and study health facilities whose access is fully subsidized. Additionally, we study a con-
text where the prevalence of substance-abuse-related mortality is very different from that
observed in the U.S.. Brazil is one of the countries with the lowest overdose death rates in
the world (UNODC, 2013). However, it has a high prevalence rate of heavy episodic drink-
ing, one of the most important indicators for acute consequences of alcohol abuse (WHO,
2019).
Our paper also contributes to the literature linking crime and mental health or mental
health services. Eighty years ago, before the advent of full-scale deinstitutionalization, Pen-
rose (1939) found a negative correlation between the proportion of people placed in mental
hospitals and the proportion held in prison using cross-country data from European coun-
tries. Since then, the Penrose’ Hypothesis has been a subject of interest and controversy
(Lamb, 2015). Using similar data, some papers found similar results (Mundt et al., 2015;
Markovitz, 2006; Raphael and Stoll, 2013), while others did not (Large and Nielssen, 2009).
A more clear pattern has been found by medical researches that use individual-level data
from discharged patients. These papers have systematically reported a high prevalence rate
of violence among former inpatients in a post-discharge period (e.g., Link et al. (1992), Fleis-
chman et al. (2014)). Most of these papers have focused on cross-sectional comparisons,
which might be subject to omitted variable bias that can affect both crimes and in-patient
care utilization. The only paper aiming a causal interpretation for the relation between men-
tal hospitalization and crime is Landerso and Fallensen (2020). But, instead of studying
discharge, they analyze the event of admission at a psychiatric hospital and find that in-
patient admittance reduces criminal behavior through incapacitation. Our paper exploits
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potentially exogenous changes in severe mental hospital admissions induced by CAPSs’ in-
troduction to study the relation between dehospitalization and homicides in the presence of
alternative, community-based treatment.
The remainder of the paper is organized as follows. Section 2 describes the institutional
background. Section 3 presents the data sources and discuss expected effects. Section 4 de-
scribes the empirical approach. In Section 5 we present and discuss our main results. Section
6 presents heterogeneous effects by different CAPSs’ types. Section 7 presents robustness
checks. Section 8 concludes.
2 Background
2.1 Institutional Background
Since the mid-20th century, many countries started to shift mental health care away from psy-
chiatric hospitals toward community-based care – in what became known as deinstitution-
alization. The rationale behind this change was based on several assumptions: community-
based care is more human than inpatient care, given the miserable condition of people in
psychiatric hospitals; community-based care is more adequate than hospital-based care in
general; and community-based care is cheaper than care provided by hospitals (Lamb and
Bachrach, 2001). This new paradigm also influenced Brazilian psychiatrists, which ulti-
mately led, in 1989, representative Paulo Delgado to present a bill to the Congress proposing
the progressive substitution of psychiatric hospitals by other, community-based resources.
The psychiatric reform bill, with some modifications, eventually became a law – Law
10.216, or the Psychiatric Reform Law – in April 2001, having the CAPSs as its centerpiece.
During this period, some states passed laws in the same spirit and some CAPSs and other
related services were created (Britto, 2004). However, only after the Psychiatric Reform Law
was passed in 2001 and a Regulatory Ordinance was issued by the Ministry of Health in
2002 the construction of CAPSs gained traction and started to happen all over the country
(BRAZIL. Ministry of Health, 2005).2 Figure 1 shows the number of municipalities receiving
a CAPS by year, from 2002 to 2016. According to the Brazilian Ministry of Health (BRAZIL.
Ministry of Health, 2015), about 900 million Brazilian Reais (BRL) were spent with this policy
2Actually, CAPS existed even before the bill was presented: the first CAPS was created in the city of São
Paulo in 1987. However, as already mentioned, the number of CAPSs before 2002 is negligible compared to
the number of centers that were created after the Psychiatric Reform Law.
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from 2002 to 2014.3
The main goal of the Brazilian psychiatric reform was to implement community-based
care services for mental health and substance misuse through CAPSs while facilitating dein-
stitutionalization from hospitals. CAPSs also became the main gateway to the public mental
health system, referring less severe cases to the Basic Healthcare Units and more severe
cases to public hospitals.4 The Regulatory Ordinance of 2002 defined six different CAPSs’
types, based on municipality size and target population. The basic and most common type
of CAPS is CAPS I, for all ages and cities with 15,000 people or more. The other general type
of CAPS are CAPS II and CAPS III, aimed at people of all ages and cities with 70,000 people
or more and 150,000 people or more, respectively. There are also CAPSs’ types for specific
groups of people. CAPS i are specialized in children and teenagers, while CAPS AD and
CAPS AD III are specialized in substance abuse treatment.
The Regulatory Ordinance of 2002 also defined that the federal government should pro-
vide financial support for the construction of the centers, and then monthly financial support
for their maintenance. For construction, financial support varies from 800,000 to 1,000,000
BRL. For maintenance, monthly support varies from 30,000 to 100,000 BRL. In order to get
a CAPS and the financial support, a municipality must send an application to the federal
government, which then approves it or not. We had access to the decisions made by the
federal government in 2019. Very few proposals were rejected. Among those rejected, the
main reason for rejection was the population criterion.
In general, all types of CAPSs deliver care following standard procedures. When a pa-
tient visits a CAPS for the first time, he/she is interviewed by a professional responsible
for giving an initial diagnosis. If it is decided that the patient will be treated in CAPS,
a multidisciplinary team – composed mainly of psychiatrists, psychologists, occupational
therapists, and social workers – takes care of the case. Then, it develops actions related to
the patient’s needs, such as consultations with a psychologist, medication use, participation
in therapeutic workshops, clinical exams, and group therapies. Overall, mental health treat-
ment delivered at CAPSs has as an explicit goal the social reintegration of individuals into
the society and the strengthening of community and family ties.
Following a similar logic, the centers also deliver substance abuse treatment, with Psy-
3Approximately US$ 220 million.
4The primary care offered by the public system in Brazil is organized around units called Basic Healthcare
Units (or UBS).
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chosocial Care Centers Alcohol and Drugs (CAPSs AD) being designed specifically for such
purpose. In particular, they offer individual and group care, as well as home visits and
outpatient detoxification. Still, these centers can work in partnership with hospitals, refer-
ring more severe cases for inpatient detoxification. The multidisciplinary teams from CAPSs
adopt several prevention practices aiming to reduce the abuse of substances by its patients.
They carry out educational activities to warn about the consequences of alcohol and other
drug abuse, offer alternative leisure activities such as physical activities and crafts, and work
with the community and the patient’s family to reduce risk factors associated with substance
abuse.
Finally, there are a few differences between the different CAPSs’ types regarding infras-
tructure. CAPSs III and CAPSs AD III are the only centers that open on weekends and de-
liver night care; the other centers operate from Monday to Friday in two 4-hour shifts. They
are also the only centers with ambulatory beds that can shelter patients needing monitoring.
2.2 Conceptual Background
Since the main component of the psychiatric reform are the CAPSs and we exploit their im-
plementation to assess the effects of the reform, it is important to understand conceptually
how these centers may affect the outcomes of interest and how we can empirically investi-
gate these channels.
In the "first-stage", the implementation of a CAPS may affect the supply of mental health
practitioners – in particular, psychiatrists, psychologists, social workers, and occupational
therapists. As CAPSs should offer treatment through a multi-disciplinary team constituted
mainly from these professionals, we expect a positive effect. We have in mind, though, that
this could not be the case if local governments were just reallocating mental health practi-
tioners from other sectors to work at CAPSs. Then, we will investigate the per capita number
of ambulatory services provided by mental health professionals. If CAPSs are indeed ef-
fective at increasing the availability of outpatient mental healthcare, we should expect to
see an increase in these outcomes. This would be consistent with previous research which
found that the strengthening of primary care in Brazil led to greater utilization of ambula-
tory services (Bhalotra et al., 2019; Carrillo and Feres, 2019; Mattos and Mazetto, 2019). We
will also look at the rate of dispensed antipsychotic drugs in the outpatient-level of care.
The rationale stems from the fact that antipsychotic drugs are the mainstay of the treatment
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for psychotic illnesses such as schizophrenia. Thus, if the introduction of community-based
mental healthcare is associated with increased utilization of outpatient care among severe
mentally ill persons, we should expect positive effects on the number of publicly dispensed
antipsychotic drugs.
If the reform is affecting the delivery of mental healthcare in the intended way, we should
see an effect of CAPSs on mental hospital admissions. This effect may be associated to
supply- and demand-driven declines in hospitalizations due to mental illness. Since one
of the psychiatric reform’s goals is to replace inpatient care, it is possible that the CAPSs’
establishment in a municipality is followed by the closure of psychiatric beds, which in turn
could lead to a reduction in hospitalizations. We can empirically test such a hypothesis. We
can also estimate the CAPSs’ effects on hospitalizations rates due to mental illness and look
for heterogeneous effects according to some groups of causes within mental illnesses.
As previously mentioned, CAPSs also became the first point of entry into publicly funded
mental health services after the Psychiatric Reform Law. So, if they have increased access
to mental health care, they may also have increased hospital admissions by referring more
previously under-served individuals to inpatient care. However, this should happen only
for exceptional cases, so we do not expect this to be a major driver behind our results. Sev-
eral studies suggest that community-based care through outpatient services may substitute
hospital admission related to mental illness. In particular, researchers often advocate that
community mental health services provide a filter-effect along the pathway to inpatient care
(Shaeffer et al., 1978; Wanchek et al., 2011; Madianos and Economou, 1999). Thus, if the
CAPSs’ opening is associated with increased utilization of outpatient mental healthcare,
we expect an increase in the number of treatments delivered in the community, reducing
demand-driven inpatient care.
All the aforementioned effects constitute the channels through which mental health can
be affected, which is the ultimate goal of the reform. We can evaluate this effect on mental
health by looking at mortality outcomes. Premature death among individuals with mental
disorders can be related to several chronic conditions such as cardiovascular, respiratory,
and infectious diseases, diabetes and hypertension. However, these conditions are not just
related to mental illness. Therefore, we evaluate causes of death more directly associated
with mental health, all of them recently entitled under the label "deaths of despair" (Case
and Deaton, 2015, 2017; Ruhm, 2018). More specifically, we evaluate suicide, overdose, and
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alcoholic liver disease.
The literature has reported striking associations between mental illness and suicide, as
well as high prevalence rates of comorbidity between substance use disorders and other
mental and behavioral disorders. To put it in perspective, it has been found that about
90% of suicides are associated with a psychiatric illness (Cavanagh et al., 2003), and that
the proportion of schizophrenic individuals with substance abuse disorders can reach 70%
(Winklbaur et al., 2006). Following Case and Deaton (2015, 2017) we also consider a broader
definition of alcohol-related mortality, by incorporating deaths coded as unspecified sources
of chronic liver diseases into the alcoholic liver disease category. In particular, chronic hep-
atitis and cirrhosis.5 Finally, we also investigate deaths coded with an underlying primary
cause of mental and behavior disorders.
The expected effects of CAPSs on mortality rates depends on how centers affected the
demand for mental health care and the effectiveness of CAPSs’ care relative to alternatives
to prevent deaths by these causes. The effects are far from obvious. If CAPSs increased the
demand for mental health care, and these centers are suitable to prevent deaths related to
mental illness among individuals that, in the absence of CAPSs, would not be demanding
mental healthcare, we should expect a decrease in mortality rates. If the CAPSs’ introduction
in a municipality causes a shift from inpatient to community-based care, and both types of
care are not perfect substitutes, the effects may be ambiguous.
The effects may also depend on the type of mental health services provided at CAPSs and
the specific cause of death being evaluated. While et al. (2012) and Pirkola et al. (2009) re-
port a positive association between community care and suicide prevention in the presence
of well-developed community mental-health services. In particular, the results presented by
Pirkola et al. (2009) are driven by the provision of community services available 24 hours a
day. In our setting, only CAPSs III and CAPSs AD III deliver night care and stay open on
weekends. These centers are available for only 3 percent of the Brazilian municipalities.6
Thus, it is possible that the association between community-based care and suicide is not
present in our context. Previous research has also shown that service-related risk-factors
for suicide include poor continuity of care in the community after hospital admissions, non-
adherence to treatment, reduced care in the community, and short length of inpatient care
5As suggested by Ruhm (2019), this definition may be too broad since the added deaths will not necessarily
involve alcohol.
6Based on the last Brazilian Census (2010), only 187 cities – out of 5570 – had at least 150,000 inhabitants.
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(Bassett and Tsourtos, 1993; Hunt et al., 2009; King et al., 2001). Hence, the CAPSs’ effects
on suicide may be positive or negative depending on the quality of care provided in both
mental health centers and hospitals, and which of these types of care are more adequate to
prevent deaths caused by suicide.
Besides suicide, the others causes of death we investigate are related to substance abuse.
As improved mental health may reduce substance abuse, any CAPS providing mental health
treatment has the potential to reduce substance-abuse-related deaths. However, the CAPSs
Alcohol and Drugs (AD) were created specifically to deliver substance abuse treatment.
Swensen (2015) shows that increased supply of mental units providing substance abuse
treatment reduced drug-related deaths in the U.S. Similarly to our context, the treatment
facilities studied by the author deliver mostly outpatient treatment services, but may also re-
fer more severe cases to residential and hospital inpatient settings. Hence, it is possible that
similar effects are also present in our context. Yet, one may also consider that the CAPSs’ ef-
fects on substance-abuse-related mortality depend on the incidence of causes CAPSs might
prevent. Differently from the U.S. context, overdose is an extremely rare event in Brazil.
In the period 2002-2016, such cause of death corresponded to only 0.05% of total deaths.
The fraction attributed to alcoholic liver disease is 0.83% (1.7% if we consider the broader
definition).
Given the depicted pattern, we should expect that the introduction of CAPSs AD is more
likely to be associated with a decrease in alcohol-related deaths than other drug-related
deaths. Indeed, the literature reports that alcoholic cirrhosis deaths can be entirely pre-
ventable by treatment for alcohol use disorders (e.g., Rehm et al. (2013)). Still, the devel-
opment of the disease into more severe stages takes some time. Therefore, we do not ex-
pect that CAPSs AD would prevent future comorbidities among healthy individuals in the
short run. The climbing of liver disease among individuals already compromised by alco-
hol abuse, however, can be deterred. According to experts, liver cirrhosis has no cure and
is associated with high mortality rates. However, a prolonged life expectancy exceptionally
requires patients to stop drinking. Any medical and surgical treatments for alcoholic liver
disease are limited when drinking continues (Addolorato et al., 2016; Tilg and Day, 2007).
Empirical evidence on the topic indicates that abstinence increases the survival rates of pa-
tients with alcoholic cirrhosis, even in the short run (Xie et al., 2014). Hence, if treatment
delivered at CAPSs effectively reduces alcohol abuse, the centers’ adoption may cause a re-
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duction in mortality due to alcoholic liver disease among patients already with some liver
comorbidity. Based on reports from professionals working at CAPSs, de Souza et al. (2014)
reveal that liver cirrhosis’s prevalence is high among patients.
Finally, we analyze the CAPSs’ effects on crime using homicide rates.7 Theoretically, the
effects may again be ambiguous. The psychiatric reform may have increased homicides me-
chanically by reducing mental hospitalizations as inpatient admittance has an incapacitation
effect (Landerso and Fallensen, 2020). Such an impact may be economically significant as
there is extensive evidence in the literature that individuals with severe mental illness are at
high risk of involvement with violent crimes (Rueve and Welton, 2008). However, we study
hospital depopulation parallel to the expansion of community-based mental treatment. The
introduction of CAPSs may reduce crime if these centers are able to improve the mental
health of under-served people to the point of controlling violent behavior. Still, the impacts
depend on whether treatment meets the medical needs of crime-prone patients. This goes
back to a long-standing debate.
Severe mentally ill persons at risk of becoming criminalized need a safe and secure
setting, where staff can monitor and contain aggressive behavior, formulate an appropri-
ate treatment, and monitor psychiatric medications (Lamb, 2015). Hospitals often share
this structure. Some specialists advocate that these needs can also be met in community
treatment facilities provided there are enough investment (Slate et al., 2013). In particular,
Dvoskin and Steadman (1994) highlight that intensive case management available 24-hours
per day and a comprehensive array of community support services are the keys to reduce
the risk of violence by people with serious mental illness in the community. However, Lamb
and Bachrach (2001) argue that the inadequate and underfunded community treatment of
persons who are the most difficult to treat is a common reality of the deinstitutionalization
process in several countries that may have set the stage for criminalization. In Brazil, the
vast majority of CAPSs does not have the infrastructure to deal with patients in outbreak
situations. Thus, the reform may have increased violent crime by shifting away mentally
ill individuals from hospital admissions without providing structure for intensive care in
the community. Finally, persons with mental disorders may be more vulnerable to violent
situations that take place in the community. Therefore, increased risk of crime victimization
7Brazil does not have a reliable and easily accessible crime data. Still, using data compiled by the police in
two Brazilian states from 2001 to 2011, Dix-Carneiro et al. (2018) show that homicides recorded by the health
system is highly correlated with police-recorded homicides and violent crimes against the person (excluding
homicides).
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may also explain a potential association between the mental health reform and homicides
(Walsh et al., 2003).
3 Data
We employ administrative data from the Brazilian Ministry of Health. With the support of
local and regional public health agencies, the Ministry of Health is responsible for managing
different information systems that result in datasets containing records of deaths, hospital-
izations, ambulatory procedures, and health facilities. These data are described in more de-
tail next. We merge information across datasets using identifiers for municipalities, which
constitute our unit of analysis. Municipalities are the smallest administrative units in the
Brazilian political system and are the geographical level in which the policy takes place.
Since some cities were created during the period, we aggregate them into minimum compa-
rable areas.8 For ease of exposition, we will hereinafter refer to minimum comparable areas
as municipalities.
Through the Information Access Law, the Ministry of Health also provided us with data
on the implementation of each CAPS. These data cover the period between 2002 and 2019
and contain the date of opening and the type of every CAPSs active as of June 2019 created
after the CAPS law was sanctioned in 2001. A few CAPSs created before this period were
accredited to 2002. So, we were unable to distinguish municipalities that adopted a CAPS
in 2002 from those that previously adopted. Hence, we only exploit variation from 2003
onwards. Appendix Figure A.1 depicts the number of municipalities adopting a mental
health center by CAPSs’ types over time, starting in 2003. The vast majority of municipalities
with a community mental health center implemented a CAPS I (80%). Additionally, most of
the cities adopted only one center during this period (see Appendix Figure A.2).
The Hospital Information System of the Unified Health System (SIH) provides informa-
tion about hospital admissions using beds of the public health care sector. The data provide
information on admissions by municipality of residence of the patient by cause, coded us-
ing the ICD-10. The whole dataset covers the period between 1995 and 2019. Also from the
Ministry of Health, the Mortality Information System (SIM) provides data on deaths in the
country from 1996 to 2017, including causes coded using the ICD-10. We rely on the ICD
8To do so, we rely on data provided by the Institute of Applied Economic Research (IPEA).
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classification to identify causes of death and hospitalization related to mental illnesses and
group them. Table A2 summarizes the relationship between groups and ICD-10 codes.
The Ministry of Health provides detailed data on all private and public health facilities in
Brazil through the National Registry of Health Establishments (CNES). This dataset includes
information about health professionals linked to some healthcare facility, including practice
and levels of specialization. For this study, we select, for each municipality, the number of
different mental health providers that usually constitute community mental health teams:
psychiatrists, psychologists, occupational therapists, and social workers. These represent,
on average, 87% of all the professionals working at the psychosocial care centers. These
data also provide information regarding the number of hospital beds in each municipality.
We select those that, according to the registries, are specifically used for psychiatric patients.
We use the National System of Information on Ambulatory Care (SIA) to investigate the
CAPSs’ effects on outpatient mental health care. Ambulatory visits may take place in any
health facility that provides primary health services. For the period 1994-2019, SIA provides
administrative information on all ambulatory visits funded by SUS in which medical care
is provided on an outpatient basis. Severe compatibility issues limit the use of this dataset.
Microdata is at the procedure level, and many procedure codes change over time. There is
no direct way to make codes compatible. Hence, with few exceptions, we avoid evaluat-
ing specific ambulatory procedures. From 2008 onward, we are able to identify the type of
health professional that provided the outpatient care. We then select the overall number of
ambulatory services made by each of the mental health providers we are evaluating (psy-
chiatrists, psychologists, occupational therapists, and social workers) to analyze the supply
of outpatient health care. To assess indicators of compliance with the policy, we also se-
lect "psycoshocial care procedures", which are available since 2002. Those include a roll of
outpatient services (medical consultations, psychotherapy, group therapy, etc.), specifically
defined to be performed at CAPS. SIA also contains information on "outpatient pharmaceu-
tical assistance", in which drugs are dispensed for patients to use at home. We select the
number of antipsychotic drugs dispensed in each municipality.
We also use additional data on municipality characteristics to control for differential
trends in important determinants of mental health in our estimates of the CAPSs’ effects
on the outcomes of interest. The Brazilian Statistical Office (IBGE) provides estimates of
population for each municipality by year, and GDP for each municipality from 2002 to 2016.
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From the Ministry of Social Development (MDS/SAGI), we collect data on Bolsa Família Pro-
gram (PBF) spending for each municipality.9 Finally, we obtained data from the Brazilian
Ministry of Health on the age and gender composition of the municipalities’ population.
Our main sample consists of balanced yearly data for 5,180 municipalities and covers the
interval between 2002 and 2016. Table A1 provides summary statistics.
4 Study Design and Estimation Strategy
We exploit the sequential process of implementation of CAPSs starting after 2002 and adopt
a difference-in-differences (DID) strategy to analyze the effects of this intervention on public
mental health and mortality by assaults. In such a setting, researchers often employ two-way
fixed effects regression models. There are two commonly adopted specifications. In one of
them, a single treatment dummy is added to the regression. This approach has been shown
to be invalid if treatment effects are heterogeneous over time or across cohorts. In particu-
lar, the linear regression coefficient may be negative even if the treatment effect is positive
(Goodman-Bacon, 2018). The other widely used specification results from adding lags and
leads of treatment to the regression. However, estimates from these models may not be
causally interpretable (Abraham and Sun, 2018). In this paper, we follow De Chaisemartin
and d’Haultfoeuille (2020) and estimate well-defined and relevant causal parameters, robust
even if treatment effects are heterogeneous across groups or over time.10
We start defining our causal estimands of interest. Let Dmt denotes our treatment dummy.
For our main empirical strategy, it indicates whether a municipality m gained a CAPS (of any
type) for the first time in year t. We are interested in the average treatment effects across the
municipalities that sequentially implemented a mental health center after 2002. That is, (m,
t) cells such that Dmt−1 = 0 and Dmt = 1 for any pair of consecutive time periods t − 1 and t.
Let S denotes the set of switching cells and NS its cardinality.11 One of our primary causal
estimands is
βS :=
1
NS
∑
(m,t)∈S
Ymt(1)− Ymt(0), (1)
9PBF is the main conditional cash transfer policy in Brazil.
10In such a staggered design, the estimators we use are very similar to those proposed by Abraham and Sun
(2018) and Callaway and Sant’Anna (2019) (for this particular case, in a specification without covariates).
11In particular, S := {(m, t) ∈ {1, . . . , M} × {1, . . . , T} : t > 1, Dmt−1 = 0, Dmt = 1}, where M is the size of
our population and T denotes the last year of our panel.
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where (Ymt(0), Ymt(1)) are the potential outcomes without and with treatment of municipal-
ity m at period t. βS is the average treatment effect across all groups of switchers, at the time
when a groups starts receiving the treatment. We are also interested in dynamic treatment
effects. These parameters can be defined similarly to (1), by evaluating Ymt(1)− Ymt(0) one
time period or more after t across the treated (m, t) cells.12 The CAPSs’ implementation
process across the municipalities has been taking place slowly and steadily over the years.
So, we may not be able to identify longer-run effects due to compositional changes arising
from the fact that late switchers will have a lot of missing post-CAPS years. For example,
if municipalities selection timing is based on expected future gains, the dynamic effects for
early-treated cities may not be representative for those who received a CAPS later and have
missing post-CAPS data. In our primary analysis, we will look up to five post-intervention
effects. About 65 per cent of our treated units had a CAPS in operation for at least 5 years.
We also consider an estimand that restrict the dynamic effects only for cities that have at
least five periods of post-CAPS observations.13
Under a parallel trends assumption, the outcome evolution among the non-switchers can
be used as the counterfactual evolution of the switchers, and a DID estimator that compares
the outcome of both groups before and after the intervention can estimate average treatment
effects among the switchers. We now present such an estimator. For any t > 1, let St be
the set of municipalities that became treated at period t. Define Ct as the set of control
municipalities at period t − 1 that did not gain a CAPS at period t. Let NSt and NCt be the
number of municipalities in each set. We first define the DID estimator for the coohort of
municipalities that implemented a CAPS at period t:
DID(t) :=
1
NSt
∑
m∈St
(Ymt − Ymt−1)−
1
NCt
∑
m∈Ct
(Ymt − Ymt−1) . (2)
DID(t) compares the evolution of the mean outcome between t − 1 and t in two sets
of groups: the municipalities that gained a CAPS at the period t (St), and those remaining
untreated (Ct). Under the assumption that the mean outcome of municipalities in St and Ct
would envolve in parallel in the absence of CAPSs’ implementation, DID(t) estimates the
12We shall also impose additional restrictions on S . For example, t < T for the treatment effects one year
after CAPSs’ implementation.
13In this case, since the composition of municipalities is the same across all event times, longer-run dynamic
effects cannot be biased due to compositional changes. However, the loss of groups used to compute the
dynamic effects can lead to less informative inference. See Callaway and Sant’Anna (2019) for an interesting
discussion on compositional changes and dynamic effects.
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average treatment effect for the switchers of period t, at the period they became treated. We
can then define the estimator for βS , which is a weighted average of the DID(t) estimators:
DIDM :=
T
∑
t=2
NSt
NS
DID(t). (3)
De Chaisemartin and d’Haultfoeuille (2020) show that under a parallel trends assump-
tion, DIDM is an unbiased estimator for the average treatment effect among switchers, at
the time period when they switch. The estimators for the dynamic treatment effects can be
defined in a similar way, by using long-differences Ymt+k − Ymt−1, for k > 0, instead of first-
differences, provided that there are stable control municipalities in the post-CAPS periods.14
Our main estimates are based on estimators like DIDM. Additionally, we consider al-
ternative specifications based on a generalization of DIDM, which allows for the inclusion
of covariates.15 We control for determinants of mental health as local economic condition
measured by GDP per capita, and the age-by-gender composition of the municipality pop-
ulation (the share of inhabitants within each 9-year-by-gender bracket, from 10-19 up to 79
years). We also adjust for per capita spending with Bolsa Família Program. Further, we ad-
just for state-year fixed effects. Regarding inference, standard errors are computed with a
municipality-level clustered bootstrap.
Our research design uses groups whose treatment is stable to infer the trends that would
have affected switchers if they had not implemented a CAPS. This design would not be
valid only if, independent of CAPSs’ implementation, there were differential trends in time-
varying determinants of outcomes across switchers and municipalities whose treatment is
stable. This could be the case if, for example, unobserved policy changes coincided with the
arrival of the CAPSs across municipalities. To deal to some degree with those issues, some of
our estimates are based on the DIDM with covariates. By adjusting for GDP per capita and
municipality age-by-gender composition, we control for differential trends in the changes
of these health determinants, which may had coincided with CAPSs’ adoption. We also
consider more flexible trends according to Bolsa Família spending as the program started
expanding across the Brazillian municipalities in the beginning of our sample.16 Finally,
14It must exist a non-empty subset Ct+k ⊂ Ct of not-yet treated municipalities at period t+ k. This is always
satisfied in our context as there is a group of never-treated cities.
15Notice that 2 can be estimated by an OLS regression of the first differences Ymt − Ymt−1 on 1{St}. In the
DID estimator with covariates, we use residualized first differences.
16The results are the same if instead of adjusting for PBF spending, we control for poverty population
coverage of this program in the municipality.
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by adjusting for state-by-year indicators, we allow for non-parametric state-specific trends.
These may be particularly relevant in the Brazilian context as various public policies – such
as those related to education and public security – are at least partly determined at the state
level. Reassuringly, point estimates are largely unaffected by the inclusion of those covariate
specific trends, suggesting that our results are unlikely to be driven by differential trends
across switchers and non-switchers. Next, we present more formal analysis that support
our design validity.
One way to assess the plausibility of our identification assumption is to follow Galiani
et al. (2005) and Rocha and Soares (2010) and estimate a hazard model of the probability of a
municipality receiving a CAPS. We perform this estimation by modifying the data, so each
municipality leaves the sample after receiving a CAPS. Then, we estimate a logit model
controlling for a flexible polynomial of time, where the dependent variable is a dummy
indicating that a municipality received a CAPS and the independent variables are socioeco-
nomic variables. More specifically, we estimate three models considering the first, second,
and third lags of the changes in our variables of interest, as well as these variables at the
baseline year. We additionally selected some socioeconomic variables from the 2000 Census
to use as controls.17
Our goal is to evaluate whether municipalities actually applied and received a CAPS
after being subject to an economic or mental health shock, which could violate our identi-
fication assumption. Results are reported in Table A3 as marginal effects calculated on av-
erages of the independent variables. Overall, we find that some baseline characteristics are
correlated with the probability of receiving a CAPS. Municipalities with greater homicide
rates at the baseline, with more inequality (based on the Theil index), and more urban had a
greater probability of receiving a CAPS. However, the effects are quantitatively small – the
effects of one standard deviation are all smaller than two percentage points. Furthermore,
and fundamental for our identification assumption, we don’t see any correlation between
receiving a CAPS and past shocks on mental health indicators, income, and homicides rate.
This provides evidence of the validity of our empirical strategy.
More generally, we can estimate treatment effects for the treated (m, t) cells using pre-
17We consider lagged changes in rates (per 10,000 people) of: hospitalizations related to mental & behavioral
disorders; deaths related to mental & behavioral disorders; deaths related to self-inflicted injuries; deaths of
despair; homicides; and sinh−1(GDP per capita). For the independent variables at the baseline, we consider
the values of the same variables in 2003 as well as some variables we get from the 2000 Census: the Theil index,
the shares of illiterate people, poor people, and people living in rural areas in the municipality.
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CAPS periods t′ < t, to judge directly the plausibility of the underlying parallel-trends
assumption defining our DID design. De Chaisemartin and d’Haultfoeuille (2020) propose
a placebo estimator, DIDplM, that compares switchers and non-switchers before the switch-
ers switch treatment. The placebo estimator for the year before the CAPSs’ introduction, for
example, compares the outcome’s evolution from t − 2 to t − 1, in municipalities that switch
and do not switch treatment between t − 1 and t. E[DIDplM] = 0 under basically the same
assumptions that guarantee that E[DIDM] = βS .18 Following the same logic of the dynamic
estimators, we can also estimate more distant placebo effects, provided that there are stable
municipalities. In our baseline results, we estimate five placebo effects. Nearly all outcomes
we evaluate display no pre-trends. Finally, in Section 7, we show that the CAPSs’ estab-
lishment is not correlated with placebo outcomes that could reflect unobservable policies or
trends.
5 Main Results
We present our main results in graphical form, plotting together in the same figure the es-
timated dynamic treatment effects using the DIDM estimator, the estimated placebo treat-
ment effects using the DIDplM estimator, and respective 95% confidence intervals computed
with a municipality-level clustered bootstrap. We also present in the same figure, two al-
ternative specifications. First, we include non-parametric state-specific trends. Further, we
adjust for GDP per capita, PBF spending, and the age-by-gender composition of the munici-
pality population.
The different sets of results are presented in three subsections. In the first, we present
the relation between CAPSs’ implementation and indicators of access and utilization of out-
patient mental health care. In the second, we present the CAPSs’ effects on mental health
measured by hospitalization and mortality caused my mental illness and behavior disor-
ders, suicide, and substance abuse. In the third and final subsection, we present the relation
between CAPSs’ opening and homicide rates.
18We also need the existence of stable groups to estimate the placebo effects.
19
5.1 Access and Utilization of Mental Health Care
5.1.1 Psychosocial Care Procedures
Before proceeding to our main results, we first use the proposed estimation strategy to
present the relation between the CAPSs’ introduction and psychosocial care procedures,
which include a roll of outpatient services delivered at these centers. Figure 2 plots the
event-study results for this relation. Although such effects should be mechanical, they pro-
vide evidence of timing and compliance with the policy. Point estimates indicate that psy-
chosocial care procedures jump right after the introduction of CAPSs in a municipality and
then rise steadily. This evidence suggests a wide use of these centers by the local popula-
tion as soon as they are implemented. A summary parameter defined by the average of the
event-specific estimates indicates that CAPSs delivered yearly 461 (s.e. 13) procedures by
10,000 people.
We can also characterize the type of care provided at CAPSs, using a restricted sample.
Until 2012, most of the provided care were labeled as non-intensive – for patients needing
monthly assistance, semi-intensive – for weekly visits, and intensive – for patients with al-
most daily care. Appendix Figure A.3 shows that during the period 2002-2012, most visits
took place on a monthly basis (an average of 234, s.e. 8, procedures by 10,000 people), fol-
lowed by weekly care (153, s.e. 6), and then daily care (84, s.e. 3). Until 2012, psychosocial
care procedures were also registered alongside with an ICD-10 (Chapter V). Appendix Fig-
ure A.5 shows that most CAPSs’ patients had schizophrenia and mood disorders, which
consists basically of bipolarity and severe depression.
5.1.2 Mental Health Practitioners
We start by showing the policy effects on the supply of mental health practitioners. Figure
3 plots such results. Estimates presented in panel (a) indicate a remarkable increase in the
supply of psychiatrists that precedes the CAPSs’ introduction and reaches its peak one year
after the policy’s beginning, declining slowly after that. The treatment effects estimate for
the year before the policy implementation indicates a statically significant increase of 0.07
psychiatrists per 10,000 people, or a 25 percent increase compared to the average in period
-5 for the treated. One year after the CAPSs’ introduction, treatment effects are almost three
times higher: 0.19 points (70 per cent). Treatment effects decay monotonically after that,
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reaching 0.11 points by year-5. We also estimate the relation between CAPS and other men-
tal health providers that usually constitute community mental health teams: psychologists
(panel (b)), occupational therapists (panel (c)), and social workers (panel (d)). Overall, the
pattern is similar to what we have found for psychiatrists. CAPSs’ effects on the supply of
these professionals are significant and high in magnitude. As before, there are anticipation
effects, most marked at the year before the establishment of CAPSs. Treatment effects then
rise until one year after the beginning of the intervention. The number of psychologists per
10,000 inhabitants increased by 0.26 (35 per cent) in the first year after CAPSs’ adoption.
Point estimates decline until the fifth year, reaching treatment effects of 0.11–0.22 (15–30
percent), depending upon the specification. One year after the program, CAPSs’ effects on
the rates of occupational therapists and social workers are 0.09 (60 per cent) and 0.27 (61 per
cent), respectively. They remained constant in subsequent years.
Overall, our results indicate that the CAPSs’ implementation in a municipality represents
a large increase in the local supply of mental health providers. This may be particularly im-
portant for small municipalities, which lack an appropriate supply of such professionals.
Moreover, the results are in line with the best practices recommended by researchers re-
garding the supply of community-based mental health care. Studies argue that this type of
care should rely heavily on human resources, and should be based on a multidisciplinary
team (e.g., Thornicroft and Tansella (2004)).
The psychosocial care centers take some time to be built, and local governments are ex-
pected to hire new professionals in advance to work in the centers when they start operating.
We have some anecdotal evidence from private conversations with municipality health of-
ficials that this indeed frequently happens. This practice is probably the reason behind the
anticipation effects we have found. In line with this channel, we show next that overall
outpatient procedures made by mental health providers increased only after the CAPSs’ in-
troduction. This is also indicative that the practice of hiring professionals in advance shall
not cause differential pre-trends in our primary mental health outcomes.
5.1.3 Outpatient Care
After confirming that CAPSs led to a substantial increase in the supply of mental health
practitioners, we turn to the analysis of outpatient care made by these professionals, which
constitute our main indicator of the CAPSs’ effects on the usage of community-based mental
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health care. These results are shown in Figure 4. In the pre-CAPS period, estimated treat-
ment effects provide no evidence of differential trends across treated and untreated areas.
One year after the CAPSs’ introduction, the number of outpatient procedures made by men-
tal health providers increased remarkably, attaining treatment effects of 132 (197 per cent) for
psychiatrists, 75 (66 per cent) for psychologists, 18 (78 per cent) for occupational therapists,
and 34 (94 per cent) for social workers.19 The gap in the number of ambulatory procedures
made by psychiatrists decreased in the subsequent years. Contrary, the gap increased for the
procedures made by psychologists, occupational therapists, and social workers. Overall, our
results indicate that number of ambulatory procedures specific to mental health increased
remarkably after the CAPSs’ introduction in a municipality.
As most of the ambulatory procedure codes change over time, we avoid evaluating spe-
cific procedures related to mental health. There is one exception: therapeutic workshops,
whose primary goal is to reinsert patients with mental and behavior disorders into social
life. The workshops are taught by professionals with complete college and involve activ-
ities like craft, music, dance, among others. This kind of procedure can be delivered at
any primary-care health facility. Figure Appendix Figure A.5 presents the relation between
CAPSs’ opening and therapeutic workshops. In the subsequent years after the CAPSs’ in-
troduction, therapeutic workshops increased by approximately 0.7 per 10,000 inhabitants,
which is equivalent to an 60 percent increase compared to the average in the pre-CAPS
period. This result is consistent with one of the CAPSs’ goals, which is to provide more
humane mental health treatment.
Finally, we analyze the relation between CAPSs’ introduction and the dispense of an-
tipsychotic drugs. These medications are mostly used to treat schizophrenia, but they may
also be suited for other diseases that cause psychotic episodes. Figure 5 presents our event-
study plots. The number of dispensed antipsychotic medications (per 10,000 people) in-
creased steadily in treated areas one year after the CAPSs’ introduction compared to control
municipalities. Estimates are less precisely estimated for the last years. But, even if we con-
sider the lower bound of the 95%-confidence-interval, results indicate that by year-5, CAPSs
increased the rate of dispensed antipsychotic drugs by at least 7 points, or 175 per cent com-
pared to a pre-CAPS mean of 4 drugs per 10,000 people. As medical therapy is one of the
most common treatments within mental health ambulatory care, this is another evidence
19In parenthesis, we present the effects relative to the average within the treated in the pre-CAPS period.
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consistent with CAPSs increasing utilization of outpatient mental health care.
One potential concern with our difference-in-difference empirical design is whether there
was a shift of mental health providers from untreated to treated areas. This would mean that
control municipalities might also be affected by the reform by reducing the density of these
professionals. In that case, we would not only overstimate the CAPSs’ impact on the density
of mental health providers, but also on the outpatient mental health care production and,
potentially, outcomes affected by those inputs. However, the data suggest that this issue is
unlikely to be important in practice. Figure A.6 present the time series of the mental health
providers’ rate and the number (per 10,000 people) of ambulatory services made by them
for a few treated cohorts and respective control cities. The changes in providers’ density and
ambulatory care production are largely driven by increases in the number of professionals
and delivery of services in treated areas and not also by decreases in control areas.
5.2 Hospital Admissions and Mortality
Consistent with a new emphasis on community-based services to provide mental health care
after the psychiatric reform, municipalities constructing a CAPS may have closed psychiatric
beds. Such a reaction could be behind any potential effects of the policy on hospitalization
outcomes. Figure 6 presents the relation between CAPSs’ opening and psychiatric beds.
There is no evidence of differential trends in the number of psychiatric beds neither before
nor after the CAPSs’ introduction.
We then turn the analysis to the CAPSs’ effects on hospital admissions due to mental
and behavioral disorders. In Figure 7, we do observe a clear tendency for sharp reductions
in mental hospitalization rate upon the arrival of CAPSs. In the first year after the CAPSs’
establishment, the admissions rate decreased by 0.9 points in treated areas compared to con-
trol municipalities, or by 7.2 percent from the pre-CAPS mean. In the subsequent years, the
point estimates are marginally lower. Still, the average effect over the post-CAPSs period
points to a yearly reduction of 0.64 (s.e. 0.29) – 0.8 (s.e. 0.27) hospitalizations by 10,000
people, depending upon the specification. Figure 8 indicates that the CAPSs’ introduction
is mostly associated with reductions in long-stay hospitalizations (> 30 days). Differently
from overall hospitalizations, the reduction of long-stay admissions is less pronounced in
the short run, but the treatment effects are monotonically increasing over time. Our evi-
dence indicates that community-based services introduced by the centers may have shifted
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patients away from hospitals, especially those who, otherwise, would be hospitalized for an
extended period.
Figure 9 examines hospitalization results by different groups of causes. Panel (a) sug-
gests that reductions in hospital admissions due to schizophrenia primarily drive the CAPSs’
effect on hospitalization rates. These rates decreased by 0.6 points (11 per cent) in the first
year, and remained nearly constant after that. For the other groups of causes, there are very
few statistically significant and negative effects. After CAPSs’ introduction, there seems to
be a tendency for hospitalizations due to mood disorders (panel (b)) to decline in treated
areas. However, treatment effects are less precisely estimated depending upon the specifi-
cation.
Figure 10 presents the CAPSs’ effect on mental health measured by deaths caused by
suicide (panel a), alcoholic liver disease (panel b), overdose (panel c), and mental and be-
havioral disorders (d). The estimates, in general, indicate no effect. Breaking down suicides
and mental disorders by groups of cause and using a broader definition of alcohol-related
mortality do not reveal any new evidence. One may consider that mortality is an extreme
outcome in our setting. So, considering the variability of the measures, it can be that the ef-
fects exist, but are too small to be detected. In the next section, we will show that the centers
specifically designed to deliver substance abuse treatment (CAPSs AD) reduced mortality
by alcoholic liver diseases.
Our results indicate that public policies aimed at providing community mental health
care can be effective at reducing hospital admissions due to mental illness without increasing
mortality outcomes. In our context, the reduction in hospitalizations was driven by individ-
uals with schizophrenia and related disorders, who are usually high users of inpatient ser-
vices (Madianos and Economou, 1999). This is consistent with our previous results, which
indicated a frequent usage of Psychosocial care services among schizophrenic individuals
and pointed to an increase in the drugs dispensed to treat such disorder. Additionally, our
results were driven by the reduction of long-stay hospitalizations, rather then sporadic in-
patient admittance. Therefore, it seems that CAPSs shifted health care for severe mental
disorders from the inpatient level to the community. This can be seen as a positive result of
the policy since researchers indicate that community mental health care provides more hu-
mane treatment for patients. Moreover, this kind of treatment is usually cheaper. However,
a recurrent concern is that the increased presence in the community of severe mentally ill
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persons that, otherwise, would be hospitalized may positively affect local criminality. We
investigate this in the next section..
5.3 Homicides
We now access whether CAPSs affected homicide rates. Figure 11 presents the results on
mortality by assault. Estimates indicate that before CAPSs’ introduction, treated and control
municipalities had very similar trends in homicide rates. Then, the creation of CAPSs is
associated with an increase in homicides. Considering the specification without controls, we
find that one year after the CAPSs’ establishment, homicide rate increased by 0.16 points in
treated areas compared to control municipalities, or by 8 percent compared to a pre-CAPS
mean within the treated of 1.9 deaths per 10,000 people. Treatment effects rise to 0.36 (18
percent) by the fifth year. Estimated effects are marginally smaller when we control for
state-specific trends (0.23, or 12 per cent, by year-5). Further including controls does not
change much our results.
Under the assumption that the only channel by which CAPSs affect mortality by assault
is through de-hospitalization, the ratio between the CAPSs’ effects on homicides and the
CAPSs’ effects on hospital admissions due to mental illness estimates the impacts of de-
hospitalization on homicides induced by CAPSs. Considering the specification with controls
and state-specific trends, the average effects of CAPSs on mental health hospitalizations
is -0.71 (s.e. 0.22), while the effects on homicides is 0.12 (s.e. 0.04). This indicates that
every 10 de-hospitalizations per 100,000 inhabitants generates approximately 1.7 homicides.
Such a ratio remains nearly the same (19%) if we focus exclusively on admissions due to
schizophrenia.20
This estimate is quantitatively similar to evidence found in the literature, based on follow-
ups of discharged individuals from mental hospitalizations. Using U.S. data and following
mental patients during their first year after discharge from the hospital, Steadman et al.
(1998) found that the 1-year aggregate prevalence of violence among them varied between
20 and 40 percent, depending upon on the diagnoses.21 Similarly, Belfrage (1998) found rate
of 40% criminality among individuals with schizophrenia, affective psychosis or paranoia,
20The average effect of CAPSs on hospitalization due to schizophrenia (0.62, s.e. 15) is nearly identical to
the average effect on overall hospitalization rate.
21They also show that over the course of the year violence decreased for some individuals, but not for
those with a diagnosis of major mental disorder (schizophrenia and other psychoses), who did not also have a
diagnosis of substance abuse.
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in a ten-year follow-up of patients who were discharged from mental hospitals in Sweden.
Our estimate is also consistent with papers reporting exclusively violent crimes. Using Is-
raeli data, Fleischman et al. (2014) found that among 3,187 discharged schizophrenic pa-
tients, 656 (20%) were later convicted by at least one crime, with 73% of them (480) being
involved in a violent crime. Based on a Swedish sample, Fazel et al. (2009) show that the
proportion of individuals with schizophrenia committing violent crimes (in a post diagno-
sis period) is 13.2%. Similarly, Link et al. (1992) report that among former and new hospital
mental health patients in the U.S., the proportion of individuals hurting someone badly is
17 and 19 percent, respectively. Our evidence is also in line with several other researches
reporting the prevalence of violent behavior in samples of severe mentally ill. Using data
from the Australia, Sweden, U.K., and U.S., studies report similar rates, in the 20 − 40 per-
cent range (Swanson et al., 2006, 2004; Wallace et al., 2004; Belfrage, 1994; Hodgins et al.,
2007; Brekke et al., 2001; Monahan et al., 2001; Hodgins et al., 2007).
Our estimate could also be consistent with the elevated rate of victimization experienced
by persons with severe mental illness reported by the literature (Walsh et al., 2003; Silver
et al., 2005; Hodgins et al., 2007; Teplin et al., 2005). Using U.K. data, Walsh et al. (2003)
show that the prevalence of violent victimization among schizophrenic patients is 17 per-
cent. If this is the main driver of our result, we should expect a similar characterization of
the individuals who drive the effects on both hospital admissions and homicides. To shed
light on this possibility, we break down our dependent variables by individual characteris-
tics available in both datasets: age and gender. Table A4 in the Appendix presents such het-
erogeneous results for homicides (panel a), hospitalizations due to mental disorders (panel
b), and hospitalizations due to schizophrenia (panel c). In the first column, we present our
main results. Then, we first restrict the analysis to male homicides/hospitalizations (column
2). Later, we break down the outcomes based on two age categories: 15 − 39 and more than
40 (columns 3 and 4). Finally, within the age bin 15 − 39, we again restrict the analyses only
to men. We present the average effects on all these dis-aggregations.
Table A4, column (2), points to the prevalence of men as victims of homicide (96% of
the overall effects). Such composition mimics variability from the data, which consists ba-
sically of male mortality (90%). This is also true for the hospitalization results. However,
we see that 65% of the decrease in hospital admissions due to mental disorders is related to
male hospitalizations. The respective proportion for schizophrenia hospitalizations is 59%.
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Therefore, a significant share of our results is explained by a decrease in hospital admissions
of women, not represented in the mortality data. The major difference, though, relates to
heterogeneous effects by age bin. The effect on homicide is entirely driven by the death of
people between 15 and 39 years old. Differently, for hospital admissions the heterogeneous
effects based on both age categories (Age 15 − 39 and Age> 39) are statistically significant
and contribute quite similarly to the decrease of hospitalizations. By restricting the analysis
by age and gender, we can see that the increase in homicides following the CAPSs’ intro-
duction is fundamentally driven by violence against prime-aged men (96%). While CAPSs
affected negatively mental hospitalizations of prime-aged men, this explains only one third
of the CAPSs’ effects on de-hospitalization. Therefore, it is unlikely that increased victim-
ization is the main mechanism behind our results on homicides.
Overall, we find a steady and robust increase in homicide rate after the roll-out of CAPSs
across the Brazilian municipalities. As previously discussed, our results may indicate that a
significant share of mentally ill individuals not institutionalized end up getting involved in
homicides. This is consistent with the pattern of our results on hospital admissions. First, the
results were driven by long-stay hospitalizations, which may have an incapacitation effect.
Second, the results were more pronounced among patients with a severe mental disorder –
schizophrenia – usually associated with violent behavior. Still, the average effect of CAPSs
on homicides is just modest: -0.14 deaths by 10,000 people, or 7 percent relative to the pre-
CAPS mean.22 This is also consistent with studies from the literature, which highlight that
although persons with mental disorders are at increased risk of committing violent crime,
the proportion of total violence attributed to this group is quite small (e.g., Walsh et al.
(2002)).
6 Heterogeneity by CAPSs’ Types
As previously commented, most of the CAPSs opened in Brazil are of the smallest type
(CAPS I). Hence, the results presented so far are driven by the effect this specific type has on
outcomes. Next, we analyze potential heterogeneities over the CAPSs’ types.
22When put in perspective to externalities from other Brazilian policies on homicides – such as the trade
liberalization (Dix-Carneiro et al., 2018) and the transition of a market from legal to illegal (Chimeli and Soares,
2017) – our results have much lower magnitude.
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6.1 CAPSs I and II: Replicating Previous Results
CAPSs II offer the same type of care from CAPSs I. They are simply target for larger mu-
nicipalities, and thus have greater teams. Therefore, we do not expect major changes in this
case, except there is significant heterogeneity according to population size. CAPSs III addi-
tionally deliver night care for patients needing monitoring. But, as very few municipalities
implemented a CAPS III, we do not have enough variation to estimate its effects. Therefore,
we will only explore variation coming from the adoption of CAPSs I and CAPSs II. Only 5
per cent of the cities that implemented a CAPS I have also implemented other centers. For
CAPS II, though, some larger municipalities additionally adopted other types of CAPSs. To
explore variation coming only from the creation of CAPSs II, we adjust all our specifications
for the implementation of other centers. Dropping the cities that received more than one
type of CAPSs leads to very similar results.
Figure A.7 presents the effects of CAPSs I and CAPSs II on overall and long-stay mental
health hospitalizations. For both CAPSs’ types the treatment effects are negative, although
the dynamic of the results is different for overall admissions (panels a and c). For CAPSs I,
the reduction in hospital admissions is immediate: −0.7 by 10,000 people, or 6 per cent in
comparison to the baseline mean. One year latter, treatment effects are a bit higher (0.77 –
0.91, depending upon on the specification). After that, treatment effects begin to decrease
toward zero. For CAPSs II, treatment effects are lower in the beginning of the policy but
are monotonically increasing over time. By year-5, the reduction in hospitalization reaches,
according to the specification with controls and state-specific trends, 1.2 points, or 7.5 per
cent in comparison to the baseline. In both cases, the decline in hospitalizations is driven
by long-stay admissions (panels b and d). For CAPSs I, though, such composition is much
more pronounced.
Figure A.8 presents the results dis-aggregated by cause and depicts a pattern already
presented in the previous section. The policy significantly reduced hospitalizations due to
schizophrenia. Additionally, results are stable over time in all specifications we consider.
Summarizing the effects by the average of the event-times effects, we find that the reduction
ranges from 0.4 to 0.7 points, depending upon on the specification, for both types of CAPSs.
The main difference between the effects of CAPSs I and II relates to hospitalizations due
to mood disorders. For CAPSs I, we find a precisely estimated negative effect only for one
year after the CAPSs’ introduction. For CAPSs II, though, point estimates are systematically
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negative for all the event-times after the beginning of the policy. Considering the specifi-
cation with controls and state-specific trends, the average of the effects indicates an overall
reduction of 0.4 (s.e. 0.17) hospitalizations per 10,000 people, or 17 per cent in comparison
to a baseline rate of 2.4. Finally, from panel (e) we realize that the attenuation of the effects
of CAPSs I on overall mental health hospitalizations is driven by hospitalization due to sub-
stance abuse, which seem to increase some years after the CAPSs’ introduction. For CAPSs
II, the effects are flat over time. As smaller CAPSs may not offer treatment for substance
abuse disorders, they may increase inpatient care by referring patients to hospitals.
As CAPSs I and II offer similar type of care and decreased mental hospitalization rates,
we should expect, based on previous results, that both treatment variations should be as-
sociated with an increase in homicide rates. Figure A.9 indeed shows this is the case. The
estimates for CAPSs I basically replicate our previous results (panel a). The point estimates
are statistically different from zero from year-1 and then slightly increase over time. The
average of the effects for the period 0-5 indicates an increase of 0.09 (s.e. 0.04) homicides per
10,000 people considering the specification with state-specific trends and controls, where the
average rate for the pre-CAPS I period is 1.8. For CAPSs II, the dynamic of the effects is very
similar. We find that one year after the introduction of CAPSs II, homicide rate increased
by 0.18 points, or by 7 per cent compared to a pre-CAPS II mean within the treated of 2.5
deaths per 10,000 people. Treatment effects rise to 0.26 (10 per cent) by the fifth year. The
average dynamic treatment effect equals 0.19 (s.e. 0.06). The point estimates are nearly the
same in all three specifications. These evidence provide further robustness for our previous
results on homicide rates. In particular, we found similar results for different sets of treated
municipalities that implemented psychosocial care centers that had similar effects on mental
health hospitalization rates.
6.2 CAPSs AD: Substance Abuse Treatment
Now, we discuss a major difference between the different types of CAPSs, related to the
treatment of alcohol and drug abuse. The Psychosocial Care Centers Alcohol and Drugs
(CAPSs AD) are specific for such purpose. We showed in Figure A.5 that, overall, very few
procedures made in CAPSs are related to psychoactive substance abuse, in comparison to
other mental disorders. However, when one looks specifically to CAPSs AD, the pattern
is totally different. On average, 133 outpatient services (per 10,000 inhabitants) related to
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substance abuse are delivered in these centers by year (see Figure A.10). Therefore, one
may expect different results for this type of CAPS on substance-abuse-related outcomes.
Due to the low number of municipalities getting a CAPS AD III, we only evaluate CAPSs
AD. Because nearly all municipalities that opened a CAPS AD have also implemented other
types of CAPSs, we cannot discard such treated cities. Still, to capture variation coming only
from the implementation of CAPSs AD we control for the adoption of other centers.
To analyze whether, concerning substance abuse treatment, the implementation of CAPSs
AD caused a shift from hospital care to community-based care, Figure A.11 examines the ef-
fects of CAPSs AD on hospital admissions. Most point-estimates are negative, but none is
significant. The average effect over the event-times equals -0.39 (s.e. 0.36), low compared to
the pre-CAPS mean of 7.4 hospital admissions. Alternatively, the provision of community
services to treat substance abuse may have reduced admissions. Still, part of this effect was
mitigated as CAPSs AD can also refer patients to realize part of the treatment in hospital
settings. We cannot separate these two forces using our data.
Figure 12 presents our main results: the effects of CAPSs AD on substance-abuse-related
deaths. Panels (a) and (b) presents variables that constitute deaths of despair: intoxication
of alcohol and drugs (intentional – suicide, or not – overdose), and alcoholic liver disease.
In panel (c) we present the effects on deaths with primary cause coded as psychoactive sub-
stance abuse disorders. We found significant results for alcoholic liver disease (panel b).
Estimates indicate that before the establishment of CAPSs AD, treated and control munici-
palities had very similar trends in the rates of deaths caused by alcoholic liver disease. Then,
the creation of CAPSs AD is associated with a decrease on deaths caused by this condition.
Treatment effects are monotonically increasing over time, becoming statistically different
from zero from year-2: −0.06 deaths by 10,000 people, or 12 per cent compared to the av-
erage in the pre-CAPS period (main specification). By year-5 treatment effects rise to 0.09
points (18 per cent). Appendix Figure A.12 presents the results when we consider the more
broad definition of alcohol-related mortality. In this case, the point-estimates are higher
in magnitude, but treatment effects are the same in relative terms. Therefore, community-
based treatment for substance abuse disorders, as measured by the creation of CAPSs AD,
does reduce deaths by alcoholic liver disease. This is particularly important for contexts
like ours where, differently from the U.S., deaths by alcoholic liver disease are much more
common than other drug-induced deaths.
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Independent of the disease stage, abstinence from alcohol is the cornerstone of care man-
agement among individuals with alcohol-related liver disease. For end-stage liver disease,
liver transplantation is one of the only treatments available. If, somehow, liver transplanta-
tion became more accessible in the Brazilian public health system parallel the opening of the
CAPSs AD, this could be behind our results. However, we show in Appendix Figure A.13
that the rates of liver transplantations did not change following implementation of CAPSs
AD (panel a), neither when we analyze transplants performed only in persons with alcoholic
liver disease (panel b). It is unlikely that this is a relevant channel in our context.
Finally, we re-estimate the results on deaths by alcoholic liver disease using restricted
samples. As CAPSs AD are target only to larger cities, it may not be appropriate to use
the whole pool of control units, which is mostly composed of smaller cities. Figure A.14
presents the average effects over the non-negative event-times when we restrict the sample
to municipalities above the 10th, 25th, 50th, and 90th percentile of the population distribu-
tion. For municipalities in the last decile of the distribution, for example, we are left with
279 never-treated municipalities (out of 5,161) and 270 treated cities (out of 315). Overall,
the results remain remarkably stable across the different samples, both when analyze only
deaths coded as alcoholic liver disease (panel a) or consider the more broader definition for
alcohol-related mortality (panel b).
7 Robustness Checks
7.1 Alternative Specifications
Since homicides are relatively rare events, data may be very noisy in smaller cities, and re-
sults may be affected by possibly spurious outliers. To check whether this seems to be a
concern, we adopt a few alternative specifications. Appendix Figure A.15 present such re-
sults. In one of the specifications, we place more weight into municipalities with a larger
population to check whether there are relevant heterogeneous effects by population size
(panel (a)). In panel (b) we discard municipalities bellow the 10th percentile of the pop-
ulation size distribution. In another specification, we restrict the sample to municipalities
reporting positive counts of homicides in all years. (panel (c)). Finally, we winsorize data by
limiting extreme values to the 5th and 95th percentiles (panel (d)). All the results obtained
from these alternative specifications are quantitatively similar to our main results. As deaths
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due to alcoholic liver diseases are also rare events, Appendix Figure A.16 depicts a similar
exercise that confirms the stability of the results under alternative specifications.
7.2 Placebo Outcomes
One concern regarding the effects we find is that the presence of CAPS could be related to
other programs or socioeconomic shocks that might also affect our main outcomes. Indeed,
Brazil experienced a period of significant economic growth during the 2000s and, concomi-
tantly, saw other important public policies like the Bolsa Família and the Family Health Pro-
grams be created or expand substantially. However, none of the other public policies in place
during the period were directed specifically at mental health and economic shocks will not
only affect mental health indicators. Hence, we can use the proposed estimation strategy to
run placebo tests on other outcomes aside from mental health indicators and homicides, but
related to these other policies and economic conditions, to assess whether the effects we find
are due to confounders or not.
Appendix Figure A.17 presents the CAPSs’ effects on placebo outcomes. Panels (a) and
(b) depict that results on economic and socio-economic indicators measured by GDP per
capita and PBF spending per capita.23 We also investigate a few health outcomes. Previous
research has shown that other Brazilian health policies expanded or implemented during
the 2000s significantly affected inputs in the production function of infant health and infant
mortality (Carrillo and Feres, 2019; Bhalotra et al., 2019; Macinko et al., 2007). Then, panel
(c) investigates the CAPSs’ effects on infant mortality. Following Malta et al. (2007), we also
select avoidable causes of deaths due to interventions of the Brazilian Health System that
do not include mental health complications. In particular, we evaluate vaccine-preventable
diseases like Tuberculosis and Hepatitis B, and infectious diseases such as HIV/AIDS and
influenza (panel d). Previous research has also shown that other Brazilian health policies
significantly affected hospitalizations and mortality rates caused by sensitive conditions to
primary care (Rocha and Soares, 2010; Fontes et al., 2018; Hone et al., 2020). Finally, in panel
(e), we check whether the pattern of our results on homicides could be explained by local
shocks on violent causes of death reflecting, for example, increased urbanization. To do so,
we investigate another major cause of violent death: car accidents. Appendix Figures A.18
and A.19 repeat similar exercises but exploiting variation only from the establishment of
23PBF spending should be based on the number of poor families in each municipality.
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CAPSs II and CAPSs AD, respectively.
Overall, we do not find any correlation between CAPSs’ presence and the aforemen-
tioned variables, which further suggests that the effects we find are indeed due to the CAPS.
7.3 Compositional Effects
A potential challenge to the interpretation of our estimates, especially the duration effects,
relates to compositional effects. For 35 per cent of our treated units, the data contain less
than five post-intervention years. Under selective treatment timing, the dynamic effects
from early-treated cities may not be representative for the longer-run effects from munici-
palities with missing post-CAPS data. In Appendix B, we re-estimate a subset of our results
using a restricted treated-sample that includes only municipalities with at least five years
of exposure to treatment. All our main results remain remarkably similar when we explore
this alternative composition of treated cohorts. Estimates still indicate that CAPS increased
utilization of mental health outpatient care, reduced hospitalization rates due to mental ill-
ness, but increased homicide rates. These last results are also seen for CAPSs II. Finally,
CAPSs AD reduced mortality rates due to alcoholic liver disease. Taken together, evidence
presented in Appendix B indicates that compositional effects do not explain our results.
7.4 Longer Event-Study
In our main exercises, we trimmed event-time plots at +5 and -5 to mitigate major changes in
group composition. More distant events would explore variation from fewer municipalities.
To show that there is no arbitrariness behind this choice, in the Appendix C we present our
main results for an extended event study going from -8 to +8. Although for some outcomes,
the estimates are noisy for more distant periods, the dynamics of the results remain the same
in the long run.
8 Conclusion
This paper studies the Brazilian psychiatric reform, which reorganized mental health care
provision by the public system building a network of community-based services centered on
Psychosocial Care Centers (CAPSs). To identify the causal effects of this reform, we exploit
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municipality-level variation in the CAPSs’ establishment. We find that the reform increased
access and utilization of ambulatory mental health care and reduced hospitalizations due
to mental and behavioral disorders. Those reductions were more pronounced for long-stay
admissions and among patients with schizophrenia. We additionally show that the centers
delivering substance abuse treatment reduced deaths due to alcoholic liver diseases. De-
spite those positive effects, we also find an increase in homicide rates, potentially caused
by the incapacitation effects long-stay hospitalizations have on crime-prone mentally ill. To
the best of our knowledge, this paper provides the first causal evaluation of a large-scale
mental-health reform. Our estimates are thus particularly informative for many countries
facing significant deficits in the provision of mental health treatments (WHO, 2013) and
countries developing or revising deinstitutionalization interventions, which, according to
the UN (2020), should be a priority following the Covid-19 pandemic.
Our results support the view there are significant trade-offs to be considered when choos-
ing the optimal delivery of mental healthcare (Lamb, 2015). While it is outside the scope of
this paper to uncover the pitfalls of community care compared with other forms of care,
there are a few particularities of our context worth mentioning. The deinstitutionalization
process in Brazil occurred late and still needs investment. Less than three percent of Brazil-
ian municipalities have access to mental health centers that serve the population 24 hours
a day and have outpatient beds and crisis intervention services. However, such infrastruc-
ture is seen as fundamental to reducing violence by people with serious mental illness in
the community (Thornicroft and Tansella, 2013; Lamb and Weinberger, 2005; Dvoskin and
Steadman, 1994). Therefore, incorporating intensive care models into the community set-
tings, as some countries have recently done (Adamou, 2005), can be a way of improving
policy outcomes of mental-health reforms. Evaluating these interventions is left to future
work.
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Figure 1: Number of municipalities receiving a CAPS (of all types) by year
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Notes: This graph plots the number of municipalities receiving a CAPS for the first time from 2002 to 2016. A
number of CAPSs were created before the period and were accredited in 2002, explaining the spike in 2002. For
the remaining CAPSs, the accreditation coincides with opening. This data show the first date of accreditation,
or date of CAPSs’ opening for the vast majority.
Figure 2: The effects of CAPSs on psychosocial care procedures – 02-16
Average Treatment Effect:  461.47 (12.675)
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPSs’ effects on the rate of psychosocial care procedures, which
are the ambulatory services provided at the CAPSs. The Average Treatment Effect computes a simple average
of the instantaneous and dynamic effects. In parenthesis, standard errors computed with a municipality-level
clustered boot-strap.
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Figure 3: Effects of CAPSs on mental health practitioners – 05-16
(a) Psychiatrists
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(b) Psychologists
Average Treatment Effect:  0.24 (0.021)
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(c) Occupational Therapists
Average Treatment Effect:  0.10 (0.012)
Average Placebo Effect:  0.02 (0.003)
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(d) Social Workers
Average Treatment Effect:  0.27 (0.020)
Average Placebo Effect:  0.05 (0.006)
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPSs’ effects on the rate of mental health practitioners. Results
for the three different specifications considered are shown, as indicated in the graph. In the first specification,
we do not include any controls. In the second specification, controls include a set of state×year indicators. In
the third specification, it further include municipality GDP per capita, PBF speding per capita, and a series of
indicators for age-by-gender population bins. The Average Treatment Effect and the Average Placebo Effect
compute a simple average of the non-placebo and placebo effects, respectively, considering the specification
with state-specific trends and controls. In parenthesis, standard errors computed with a municipality-level
clustered bootstrap. Baseline indicates the sample mean values for the treated in the pre-CAPS period.
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Figure 4: Effects of CAPSs on outpatient care by mental health specialists – 08-16
(a) Psychiatrists
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(b) Psychologists
Average Treatment Effect:  72.49 (7.496)
Average Placebo Effect:  6.13 (1.838)
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(c) Occupational Therapists
Average Treatment Effect:  34.14 (6.824)
Average Placebo Effect:  1.36 (1.189)
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(d) Social Workers
Average Treatment Effect:  43.21 (5.301)
Average Placebo Effect:  2.20 (1.093)
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPSs’ effects on the rate of ambulatory procedures made by
mental health providers. For additional details, see Figure 3.
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Figure 5: Effects of CAPSs on dispensed antipsychotic drugs – 02-16
Average Treatment Effect:  11.93 (4.294)
Average Placebo Effect:  0.94 (0.535)
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPSs’ effects on the rate of dispensed antipsychotic drugs. These
are drugs delivered at the ambulatory level for patients, especially with schizophrenia and other psychotic
disorders, for home use. For additional details, see Figure 3.
Figure 6: Effects of CAPSs on psychiatric beds (05-16)
Average Treatment Effect:  0.07 (0.217)
Average Placebo Effect:  0.06 (0.045)
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPSs’ effects on the rate of psychiatric beds. For additional
details, see Figure 3.
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Figure 7: Effects of CAPSs on hospitalizations due to mental and behavioral disorders –
02-16
Average Treatment Effect:  -0.71 (0.222)
Average Placebo Effect:  -0.02 (0.076)
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPSs’ effects on the rate of hospital admissions due to mental
and behavioral disorders (ICD-10 F00-F99). For additional details, see Figure 3.
Figure 8: Effects of CAPSs on long-stay hospitalizations due to mental and behavioral dis-
orders (>30 days) – 02-16
Average Treatment Effect:  -0.65 (0.142)
Average Placebo Effect:  -0.04 (0.056)
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPSs’ effects on the rate of long-stay hospital admissions due
to mental and behavioral disorders (ICD-10 F00-F99). Long-stay hospitalizations are defined as those in which
the patient is hospitalized for more than 30 days. For additional details, see Figure 3.
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Figure 9: Effects of CAPSs on hospitalization by cause – 02-16
(a) Schizophrenia and Related Disorders
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(b) Mood Disorders
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(c) Neurotic and Stress-related Disorders
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(d) Psychoactive Substance Abuse Disorders
Average Treatment Effect:  0.13 (0.159)
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(e) Mental Retardation
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(f) Dementia and other Organic Disorders
Average Treatment Effect:  0.00 (0.013)
Average Placebo Effect:  -0.01 (0.009)
Baseline:  0.12
-1
.5
-1
-.5
0
.5
1
Tr
ea
tm
en
t E
ffe
ct
-5 -4 -3 -2 -1 0 1 2 3 4 5
Time Since Treatment
Main State-specific Trend State-specific Trend+Controls
Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPSs’ effects on the rate of hospital admissions due to mental
and behavioral disorders by groups of cause: schizophrenia and related disorders (F20-F29), mood disorders
(F30-F39), substance abuse disorders (F10-F19), mental retardation (F70-79), and organic disorders (F00-F09).
For additional details, see Figure 3.
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Figure 10: Effects of CAPSs on mortality by cause – 02-16
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(b) Alcoholic Liver Disease
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(c) Overdose
Average Treatment Effect:  0.00 (0.002)
Average Placebo Effect:  -0.00 (0.001)
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(d) Mental disorders
Average Treatment Effect:  -0.02 (0.021)
Average Placebo Effect:  0.01 (0.006)
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPSs’ effects on the rate of mortality due to m suicide (X60-X84),
alcoholic liver disease (K70, K73-K74), overdose (X40-X45, Y10-Y15, Y45, Y47, Y49), and mental disorders (F00-
F99). For additional details, see Figure 3.
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Figure 11: Effects of CAPSs on homicides – 02-16
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPSs’ effects on the rate of homicide (X85-Y09). For additional
details, see Figure 3.
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Figure 12: Effects of CAPSs AD on substance-abuse-related deaths – 02-16
(a) Self-inflicted Poisoning and Overdose
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(b) Alcoholic Liver Disease
Average Treatment Effect:  -0.05 (0.022)
Average Placebo Effect:  -0.01 (0.007)
Baseline:  0.49
-.1
5
-.1
-.0
5
0
.0
5
Tr
ea
tm
en
t E
ffe
ct
-5 -4 -3 -2 -1 0 1 2 3 4 5
Time Since Treatment
Main State-specific Trend State-specific Trend+Controls
(c) Psychoactive Substance Abuse Disorders
Average Treatment Effect:  0.03 (0.032)
Average Placebo Effect:  0.01 (0.006)
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPS AD effects on the rate of deaths caused by self-inflicted
poisoning and overdose (X60-X69, X40-X45, Y10-Y15, Y45, Y47, Y49), alcoholic liver disease (K70), and psy-
choactive substance abuse disorders (F10-F19). For additional details, see Figure 3.
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A Additional Figures and Tables
Figure A.1: Number of municipalities adopting CAPSs (by CAPSs’ types) by year
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Notes: These graphs plot the number of municipalities receiving a CAPS for the first time, by CAPSs’ type,
from 2003 to 2016. Due to the discrepancy between the number of municipalities receiving a CAPS I and other
types, panel (a) uses a different scale. We omit 2002 as we cannot distinguish municipalities that got a CAPS
in 2002 from those that got earlier. This data show the first date of accreditation, or date of CAPSs’ opening for
the vast majority.
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Figure A.2: Fraction of treated municipalities by the number of adopted CAPSs
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Notes: Among the municipalities that have adopted a CAPS starting in 2003, this graph plots the fraction by
the number of opened centers.
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Figure A.3: The effects of CAPSs on psychosocial care procedures by type of care– 02-12
(a) Non-intensive care (monthly visits)
Average Treatment Effect:  234.38 (7.630)
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(b) Semi-intensive care (weekly visits)
Average Treatment Effect:  152.52 (5.696)
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(c) Intensive care (daily visits)
Average Treatment Effect:  83.77 (3.072)
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPSs’ effects on the rate of psychosocial care procedures by type
of care. Until 2012, the provided care were labeled as non-intensive – for patients needing monthly assistance,
semi-intensive – for weekly visits, and intensive – for patients with almost daily care. The Average Treatment
Effect computes a simple average of the instantaneous and dynamic effects. In parenthesis, standard errors
computed with a municipality-level clustered boot-strap.
56
Figure A.4: The effects of CAPSs on psychosocial care procedures by groups of cause– 02-12
(a) Schizophrenia and Related Disorders
Average Treatment Effect:  132.52 (4.897)
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(b) Mood Disorders
Average Treatment Effect:  134.35 (4.497)
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(c) Neurotic and Stress-Related Disorders
Average Treatment Effect:  90.06 (4.044)
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(d) Psychoactive Substance Abuse Disorders
Average Treatment Effect:  27.19 (3.323)
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(e) Mental Retardation
Average Treatment Effect:  38.77 (2.071)
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(f) Organic Disorders
Average Treatment Effect:  7.13 (1.162)
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPSs’ effects on the rate of psychosocial care procedures by
groups of cause. The Average Treatment Effect computes a simple average of the instantaneous and dynamic
effects. In parenthesis, standard errors computed with a municipality-level clustered boot-strap.
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Figure A.5: Effects of CAPSs on therapeutic workshops – 02-16
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPSs’ effects on the rate of therapeutic workshops. The same
specifications from Figure 3 also apply here. The Average Treatment Effect and the Average Placebo Effect
compute a simple aver-age of the non-placebo and placebo effects, respectively, considering the specification
with state-specific trends and controls. In parenthesis, standard errors computed with a municipality-level
clustered boot-strap. Baseline indicates the sample mean values for the treated in the pre-CAPS period.
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Figure A.6: Time series of the mental health providers’ rate (06–16) and the number (per
10,000 people) of ambulatory services made by them (08–16) for three treated cohorts and
respective control cities
(a) Density of Mental Health Providers – 2010
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(b) Ambulatory Mental Health Care Produc-
tion – 2010 Cohort
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(c) Density of Mental Health Providers – 2012
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(d) Ambulatory Mental Health Care Produc-
tion – 2012 Cohort
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(e) Density of Mental Health Providers – 2014
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(f) Ambulatory Mental Health Care Produc-
tion – 2014 Cohort
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Notes: This figure plots the time series of the mental health providers’ rate and the number (per 10,000 peo-
ple) of ambulatory services made by them for a few treated cohorts and respective controls. Mental health
providers include psychiatrists, psychologists, social workers, and occupational therapists.
59
Figure A.7: Effects of CAPSs I and CAPS II on hospital admissions by mental health and
behavior disorders – 02-16
(a) CAPS I
Average Treatment Effect:  -0.52 (0.275)
Average Placebo Effect:  0.05 (0.072)
Baseline:  11.66
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(b) CAPS I (long-stay hospitalization)
Average Treatment Effect:  -0.57 (0.130)
Average Placebo Effect:  0.00 (0.047)
Baseline:  5.44
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(c) CAPS II
Average Treatment Effect:  -0.88 (0.523)
Average Placebo Effect:  -0.44 (0.276)
Baseline:  16.29
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(d) CAPS II (long-stay hospitalization)
Average Treatment Effect:  -0.53 (0.311)
Average Placebo Effect:  -0.21 (0.241)
Baseline:  7.44
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the Effects of CAPSs I (panel a) and CAPS II (panel b) on the rate
of hospital admissions due to mental and behavioral disorders (codes F00-F99). The same specifications from
Figure 3 also apply here. We additionally control for the introduction of any other type of center. The Average
Treatment Effect and the Average Placebo Effect compute a simple average of the non-placebo and placebo
effects, respectively, considering the specification with state-specific trends and controls. In parenthesis, stan-
dard errors computed with a municipality-level clustered bootstrap. Baseline indicates the sample mean val-
ues for the treated in the pre-CAPS period.
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Figure A.8: Effects of CAPSs I and CAPS II on hospital admissions by cause – 02-16
(a) CAPS I – Schizophrenia
Average Treatment Effect:  -0.65 (0.132)
Average Placebo Effect:  0.03 (0.028)
Baseline:  4.98
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(b) CAPS II – Schizophrenia
Average Treatment Effect:  -0.40 (0.193)
Average Placebo Effect:  -0.14 (0.131)
Baseline:  6.58
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(c) CAPS I – Mood Disorders
Average Treatment Effect:  -0.03 (0.105)
Average Placebo Effect:  0.01 (0.022)
Baseline:  1.49
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(d) CAPS II – Mood Disorders
Average Treatment Effect:  -0.39 (0.176)
Average Placebo Effect:  0.06 (0.052)
Baseline:  2.39
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(e) CAPS I – Substance Abuse
Average Treatment Effect:  0.24 (0.165)
Average Placebo Effect:  0.01 (0.037)
Baseline:  3.95
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(f) CAPS II – Substance Abuse
Average Treatment Effect:  -0.02 (0.227)
Average Placebo Effect:  -0.19 (0.108)
Baseline:  5.51
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the Effects of CAPSs I and II on the rate of hospital admissions due
to mental and behavioral disorders by groups of cause: schizophrenia and related disorders (F20-F29), mood
disorders (F30-F39), and substance abuse disorders (F10-F19). The same specifications from Figure 3 also apply
here. We additionally control for the introduction of any other type of center. The Average Treatment Effect
and the Average Placebo Effect compute a simple average of the non-placebo and placebo effects, respectively,
considering the specification with state-specific trends and controls. In parenthesis, standard errors computed
with a municipality-level clustered bootstrap. Baseline indicates the sample mean values for the treated in the
pre-CAPS period.
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Figure A.9: Effects of CAPSs I and CAPSs II on homicide rate – 02-16
(a) CAPS I
Average Treatment Effect:  0.09 (0.042)
Average Placebo Effect:  0.02 (0.013)
Baseline:  1.80
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(b) CAPS II
Average Treatment Effect:  0.19 (0.064)
Average Placebo Effect:  -0.04 (0.023)
Baseline:  2.53
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the Effects of CAPSs I (panel a) and CAPS II (panel b) on homicide
rates. The same specifications from Figure 3 also apply here. We additionally control for the introduction
of any other type of center. The Average Treatment Effect and the Average Placebo Effect compute a simple
average of the non-placebo and placebo effects, respectively, considering the specification with state-specific
trends and controls. In parenthesis, standard errors computed with a municipality-level clustered bootstrap.
Baseline indicates the sample mean values for the treated in the pre-CAPS period.
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Figure A.10: Effects of CAPSs AD on psychosocial care procedures related to psychoactive
substance abuse disorders – 02-12
Average Treatment Effect:  132.87 (20.098)
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This figure plots 95% confidence-intervals computed with a municipality-level clustered boot-strap and dy-
namic and placebo DID estimators for the CAPS AD effects on the rate of psychosocial care procedures related
to psychoactive substance abuse disorders. The Average Treatment Effect computes a simple average of the in-
stantaneous and dynamic effects. In parenthesis, standard errors computed with a municipality-level clustered
boot-strap.
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Figure A.11: Effects of CAPSs AD on hospitalizations due to psychoactive substance abuse
disorders – 02-16
Average Treatment Effect:  -0.39 (0.367)
Average Placebo Effect:  0.07 (0.094)
Baseline:  7.40
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPS AD effects on the rate of hospital admissions due to psy-
choactive substance abuse disorders (codes F10-F19). The same specifications from Figure 3 also apply here.
We additionally control for the introduction of any other type of center. The Average Treatment Effect and
the Average Placebo Effect compute a simple average of the non-placebo and placebo effects, respectively,
considering the specification with state-specific trends and controls. In parenthesis, standard errors computed
with a municipality-level clustered bootstrap. Baseline indicates the sample mean values for the treated in the
pre-CAPS period.
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Figure A.12: Effects of CAPSs AD on deaths due to alcoholic and unspecified sources of
chronic liver diseases – 02-16
Average Treatment Effect:  -0.09 (0.026)
Average Placebo Effect:  -0.01 (0.013)
Baseline:  1.07
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPS AD effects on mortality rates due to alcoholic and unspec-
ified sources of chronic liver diseases (codes K70, K73, K74). The same specifications from Figure 3 also apply
here. We additionally control for the introduction of any other type of center. The Average Treatment Effect
and the Average Placebo Effect compute a simple average of the non-placebo and placebo effects, respectively,
considering the specification with state-specific trends and controls. In parenthesis, standard errors computed
with a municipality-level clustered bootstrap. Baseline indicates the sample mean values for the treated in the
pre-CAPS period.
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Figure A.13: Effects of CAPSs AD on liver transplantation rate – 02-16
(a) Liver transplantation
Average Treatment Effect:  -0.00 (0.005)
Average Placebo Effect:  0.00 (0.001)
Baseline:  0.04
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(b) Liver transplantation only to individuals
with alcoholic liver disease
Average Treatment Effect:  -0.00 (0.004)
Average Placebo Effect:  0.00 (0.001)
Baseline:  0.03
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the Effects of CAPSs AD on liver transplantation rate (panel a) and
on the rate of liver transplantation performed in individuals with alcoholic liver disease (panel b). The same
specifications from Figure 3 also apply here. We additionally control for the introduction of any other type of
center. For the third specification, the average effects over the non-placebo even-times are the following. The
Average Treatment Effect and the Average Placebo Effect compute a simple average of the non-placebo and
placebo effects, respectively, considering the specification with state-specific trends and controls. In paren-
thesis, standard errors computed with a municipality-level clustered bootstrap. Baseline indicates the sample
mean values for the treated in the pre-CAPS period.
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Figure A.14: Average effects of CAPSs AD on the rate of deaths caused by alcoholic liver
disease – 02-16
(a) Alcoholic liver disease
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(b) Alcoholic and chronic liver disease
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
the average treatment effect of CAPSs AD on deaths due to alcoholic liver disease (panel a; code K70) and
alcoholic and unspecified sources of chronic liver diseases (panel b; codes K70, K73, K74). We present the
results for different sample restrictions. In particular, we restrict the sample to municipalities above the 10th,
25th, 50th, 75h, and 90th percentile of the population distribution. Average treatment effect is defined by the
average of the effects for the non-negative event-times. The same specifications from Figure 3 also apply here.
We additionally control for the introduction of any other type of center.
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Figure A.15: Effects of CAPSs on homicide - 02-12
(a) Weighting by population size
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(b) Discarding small municipalities
Average Treatment Effect:  0.10 (0.044)
Average Placebo Effect:  0.02 (0.010)
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(c) Discarding municipalities with no homi-
cides trough the panel
Average Treatment Effect:  0.12 (0.040)
Average Placebo Effect:  0.01 (0.010)
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(d) 90% winsorization
Average Treatment Effect:  0.07 (0.035)
Average Placebo Effect:  0.01 (0.012)
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPSs’ effects on homicides, for different specifications. In panel
a, we present estimates weighted by the baseline population size; in panel b, we discard municipalities bellow
the 10th percentile of the population size distribution; in panel c, we restrict the sample to municipalities
reporting positive counts of homicides rates in all years; and in panel d, we set data below the 5th percentile to
the 5th percentile, and set data above the 95th percentile to the 95th percentile. Regarding covariates, the same
specifications from Figure 3 also apply here. The Average Treatment Effect and the Average Placebo Effect
compute a simple average of the non-placebo and placebo effects, respectively, considering the specification
with state-specific trends and controls. In parenthesis, standard errors computed with a municipality-level
clustered bootstrap. Baseline indicates the sample mean values for the treated in the pre-CAPS period.
68
Figure A.16: Effects of CAPSs AD on the rate of deaths caused by alcoholic liver disease-
02-12
(a) Weighting by population size
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(b) Discarding small municipalities
Average Treatment Effect:  -0.05 (0.021)
Average Placebo Effect:  -0.01 (0.007)
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(c) Discarding municipalities with no deaths by
alcoholic liver disease trough the panel
Average Treatment Effect:  -0.05 (0.017)
Average Placebo Effect:  -0.01 (0.008)
Baseline:  0.49
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(d) 90% winsorization
Average Treatment Effect:  -0.04 (0.019)
Average Placebo Effect:  -0.01 (0.007)
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPSs’ effects on the rate of deaths caused by alcoholic liver
disease (code K70), for different specifications. In panel a, we present estimates weighted by the baseline
population size; in panel b, we discard municipalities bellow the 10th percentile of the population size dis-
tribution; in panel c, we restrict the sample to municipalities reporting positive counts of deaths by alcoholic
liver disease in all years; and in panel d, we set data below the 5th percentile to the 5th percentile, and set data
above the 95th percentile to the 95th percentile. Regarding covariates, the same specifications from Figure 3
also apply here. The Average Treatment Effect and the Average Placebo Effect compute a simple average of
the non-placebo and placebo effects, respectively, considering the specification with state-specific trends and
controls. In parenthesis, standard errors computed with a municipality-level clustered bootstrap. Baseline
indicates the sample mean values for the treated in the pre-CAPS period.
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Figure A.17: Effects of CAPSs on placebo outcomes – 02-16
(a) Municipality GDP per capita
Average Treatment Effect:  0.00 (0.004)
Average Placebo Effect:  0.00 (0.001)
Baseline:  2.65
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(b) PBF speding per capita
Average Treatment Effect:  -0.01 (0.008)
Average Placebo Effect:  -0.00 (0.002)
Baseline:  4.40
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(c) Infant mortality
Average Treatment Effect:  1.55 (2.792)
Average Placebo Effect:  0.01 (1.007)
Baseline:  173.41
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(d) Deaths due to vaccine-preventable diseases
and infectious diseases
Average Treatment Effect:  -0.06 (0.067)
Average Placebo Effect:  -0.07 (0.024)
Baseline:  8.14
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(e) Deaths due to car accidents
Average Treatment Effect:  0.02 (0.029)
Average Placebo Effect:  -0.03 (0.008)
Baseline:  1.55
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the effects of CAPSs on municipality GDP per capita (panel a) and
PBF spending per capita (panel b), infant mortality (panel b), deaths due to vaccine-preventable diseases and
infectious diseases (panel d), and deaths due to car accidents (panel e). The Average Treatment Effect and
the Average Placebo Effect compute a simple average of the non-placebo and placebo effects. In parenthesis,
standard errors computed with a municipality-level clustered bootstrap. Baseline indicates the sample mean
values for the treated in the pre-CAPS period.
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Figure A.18: Effects of CAPSs II on placebo outcomes – 02-16
(a) Municipality GDP per capita
Average Treatment Effect:  0.02 (0.008)
Average Placebo Effect:  0.01 (0.003)
Baseline:  2.93
-.0
4
-.0
2
0
.0
2
.0
4
Tr
ea
tm
en
t E
ffe
ct
-5 -4 -3 -2 -1 0 1 2 3 4 5
Time Since Treatment
(b) PBF speding per capita
Average Treatment Effect:  -0.01 (0.024)
Average Placebo Effect:  -0.00 (0.006)
Baseline:  3.60
-.1
-.0
5
0
.0
5
.1
Tr
ea
tm
en
t E
ffe
ct
-5 -4 -3 -2 -1 0 1 2 3 4 5
Time Since Treatment
(c) Infant mortality
Average Treatment Effect:  -0.51 (3.742)
Average Placebo Effect:  0.74 (1.003)
Baseline:  164.14
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(d) Deaths due to vaccine-preventable diseases
and infectious diseases
Average Treatment Effect:  0.03 (0.079)
Average Placebo Effect:  -0.02 (0.039)
Baseline:  8.74
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(e) Deaths due to car accidents
Average Treatment Effect:  -0.08 (0.051)
Average Placebo Effect:  -0.02 (0.016)
Baseline:  1.55
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the effects of CAPSs II on municipality GDP per capita (panel a) and
PBF spending per capita (panel b), infant mortality (panel c), deaths due to vaccine-preventable diseases and
infectious diseases (panel d), and deaths due to car accidents (panel e). The Average Treatment Effect and
the Average Placebo Effect compute a simple average of the non-placebo and placebo effects. In parenthesis,
standard errors computed with a municipality-level clustered bootstrap. Baseline indicates the sample mean
values for the treated in the pre-CAPS period.
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Figure A.19: Effects of CAPSs AD on placebo outcomes – 02-16
(a) Municipality GDP per capita
Average Treatment Effect:  0.00 (0.007)
Average Placebo Effect:  0.01 (0.003)
Baseline:  3.15
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(b) PBF speding per capita
Average Treatment Effect:  -0.02 (0.021)
Average Placebo Effect:  -0.00 (0.006)
Baseline:  3.92
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(c) Infant mortality
Average Treatment Effect:  -0.10 (3.103)
Average Placebo Effect:  0.16 (0.948)
Baseline:  152.56
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(d) Deaths due to vaccine-preventable diseases
and infectious diseases
Average Treatment Effect:  0.08 (0.117)
Average Placebo Effect:  -0.03 (0.044)
Baseline:  9.98
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(e) Deaths due to car accidents
Average Treatment Effect:  -0.06 (0.048)
Average Placebo Effect:  -0.04 (0.014)
Baseline:  1.68
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the effects of CAPSs AD on municipality GDP per capita (panel a)
and PBF spending per capita (panel b), infant mortality (panel b), deaths due to vaccine-preventable diseases
and infectious diseases (panel d), and deaths due to car accidents (panel e). The Average Treatment Effect and
the Average Placebo Effect compute a simple average of the non-placebo and placebo effects. In parenthesis,
standard errors computed with a municipality-level clustered bootstrap. Baseline indicates the sample mean
values for the treated in the pre-CAPS period.
72
Table A1: Descriptive Statistics – baseline year (2002, except where noted)
All Treated Never Treated
Hospitalizations (per 10,000 pop.)
Mental and behavioral disorders 14.89 13.90 14.89
Schizophrenia 6.59 6.46 6.54
Mood Disorders 1.70 1.50 1.73
Stress-related disorders 0.10 0.12 0.09
Psychoactive substance abuse 4.79 4.31 4.82
Mental retardation 0.22 0.21 0.20
Dementia 0.19 0.21 0.18
Others 1.29 1.10 1.32
Mortality (per 10,000 pop.)
Suicide 0.56 0.45 0.60
Overdose 0.01 0.01 0.01
Alcoholic and chronic liver diseases 0.74 0.77 0.70
Mental and behavioral disorders 0.40 0.39 0.40
Homicide 1.29 1.70 1.06
Outpatient Care (per 10,000 pop.)
By psychiatrists (2008) 30.84 45.44 28.47
By psychologists (2008) 77.56 67.05 79.27
By social workers (2008) 29.03 23.38 29.95
By occupational therapists (2008) 19.85 18.78 20.03
Antipsychotic drugs 0.77 0.55 0.16
Mental Health Facilities (per 10,000 pop.)
Psychiatrists (2006) 0.21 0.30 0.14
Psychologists (2006) 0.86 0.65 0.89
Social workers (2006) 0.59 0.47 0.60
Occupational therapists (2006) 0.11 0.14 0.07
Psychiatric beds (2006) 0.85 1.57 0.28
To be continued
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Table A1 (continued)
All Treated Never Treated
Municipalities’ Characteristics
Number of municipalities 5180 1344 3836
Population 31007 43884 9437
Men 0.51 0.50 0.51
Age 10–19 0.19 0.20 0.19
Age 40–49 0.12 0.12 0.12
Age 70–79 0.04 0.03 0.04
PBF per capita 4.02 4.08 4.05
GDP per capita 2.26 2.28 2.22
Notes: All tabulations refer to the baseline year (2002), except where noted. Treated includes the cohorts of
municipalities that implemented a CAPS for the first time in the period 2003-2016. Men, Age 10–19, Age 40–
49, and Age 70–79 represent the fraction of the population that are men, and the fraction within each age bin
(10-19, 40-49, and 70-79).
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Table A2: Groups of Mortality and Morbidity Causes and Associated ICD-10 Codes
Group ICD-10 Codes
Mental and behavioral disorders
F00-F09: Organic, including symptomatic, mental
disorders
F10-F19: Mental and behavioral disorders due to
psychoactive substance abuse
F20-F29: Schizophrenia, schizotypal and delusional
disorders
F30-F39: Mood disorders, including major depres-
sive disorder and bipolar disorder
F40-F48: Neurotic, stress-related and somatoform
disorders
F50-F59: Behavioral syndromes associated with
physiological disturbances and physical factors
F60-F69: Disorders of adult personality and behavior
F70-F79: Mental retardation
F80-F89: Disorders of psychological development
F90-F98: Behavioral and emotional disorders with
onset usually occuring in childhood and adoles-
cence
F99: Unspecified mental disorder
Homicide X85-Y09: Assault, excluding injuries due to legal in-
tervention and operations of war
Deaths of Despair
X40-X45, Y10-Y15, Y45, Y47, Y49: Alcoholic poison-
ing and overdose of prescription and illegal drugs
X60-X84: Suicide
K70: Alcoholic liver disease
K73, K74: Unspecified chronic liver disease
75
Table A3: Hazard estimation of probability of receiving a CAPS (marginal effects)
(1) (2) (3)
A. Lagged variables (per 10,000 people)
∆−1Hosp: Mental & Behavioral Disorders 0.00008
(0.00008)
∆−1Deaths: Mental & Behavioral Disorders -0.00006
(0.00051)
∆−1Deaths of Despair 0.00015
(0.00042)
∆−1Homicides -0.00008
(0.00034)
∆−1arcsinh(GDP per capita) 0.00143
(0.00457)
∆−2Hosp: Mental & Behavioral Disorders -0.00002
(0.00009)
∆−2Deaths: Mental & Behavioral Disorders 0.00034
(0.00054)
∆−2Deaths of Despair -0.00023
(0.00045)
∆−2Homicides 0.00036
(0.00036)
∆−2arcsinh(GDP per capita) 0.00315
(0.00486)
∆−3Hosp: Mental & Behavioral Disorders -0.00009
(0.00009)
∆−3Deaths: Mental & Behavioral Disorders 0.00000
(0.00053)
∆−3Deaths of Despair -0.00005
(0.00044)
∆−3Homicides 0.00025
(0.00036)
∆−3arcsinh(GDP per capita) 0.00598
(0.00475)
B. Variables at baseline
Theil Index (2000) 0.06141 0.06020 0.04973
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Table A3 – Continued
(1) (2) (3)
(0.00562) (0.00601) (0.00610)
Share Illiterate (2000) -0.02865 -0.02497 -0.01717
(0.01405) (0.01479) (0.01483)
Share Poor (2000) -0.04439 -0.04626 -0.03486
(0.00892) (0.00941) (0.00928)
Share Rural (2000) -0.06102 -0.05955 -0.05721
(0.00445) (0.00467) (0.00477)
Hosp: Mental & Behavioral Disorders (2003) 0.00005 0.00005 0.00002
(0.00004) (0.00005) (0.00005)
Deaths: Mental & Behavioral Disorders (2003) -0.00006 -0.00008 -0.00018
(0.00086) (0.00090) (0.00089)
Deaths of Despair (2003) 0.00074 0.00081 0.00093
(0.00063) (0.00066) (0.00064)
Homicides (2003) 0.00241 0.00249 0.00204
(0.00037) (0.00040) (0.00040)
arcsinh(GDP per capita) (2003) -0.00044 -0.00097 0.00021
(0.00139) (0.00150) (0.00149)
Observations 53,096 48,045 43,089
State FE Yes Yes Yes
Time Polynomial Degree 5 5 5
Notes: Marginal effects of the hazard estimation of probability of receiving a CAPS. In this sample, covering
the period from 2003 to 2016, units appear in the data until they receive a CAPS and, after that, they leave
the sample. Each specification considers a different lagged difference of the main variables of interest and
control for their baseline values, as well as the baseline values of other variables of interest as indicated in the
table. A logit model is estimated and the reported marginal effects are taken at the average of each variable.
Observations at the municipality level.
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Table A4: Heterogeneous CAPSs’ effects on homicide rates and hospital admissions
Overall Male Age 15-39 Age> 39 Male & Age 15-39
(1) (2) (3) (4) (5)
Panel (a): Homicides
Avgerage Effects 0.120 0.116 0.120 -0.010 0.116
(0.04) (0.04) (0.03) (0.01) (0.02)
Pre-CAPS mean of the outcome 1.96 1.76 1.37 0.45 1.25
Panel (b):Hosp. by Mental Disorders
Avgerage Effects -0.71 -0.459 -0.340 -0.350 -0.236
(0.22) (0.21) (0.14) (0.12) (0.12)
Pre-CAPS mean of the outcome 12.61 8.44 6.77 5.73 4.66
Panel (c):Hosp. by Schizophrenia
Avgerage Effects -0.624 -0.364 -0.328 -0.294 -0.209
(0.10) (0.11) (0.08) (0.05) (0.05)
Pre-CAPS mean of the outcome 5.32 3.24 2.81 2.47 1.91
Note: This table report the average effects of CAPSs on homicide rates (panel a; codes X85-Y09), hospi-
tal admissions by mental and behavioral disorders (panel b; codes F00-F99), and hospital admissions by
schizophrenia (panel c; codes F20-F29). The average effects are defined by the average of the DID estimators
for the non-negative event-times. Standard errors in parenthesis are computed using a municipality-level
clustered boostrap. Column 1 presents the results on overall mortality and admission rates. Column 2 con-
sider only male homicides/admissions. Later, we break down the outcomes based on two age categories:
15-39 and more than 40 (columns 3 and 4, respectively). Finally, within the age bin 15-39, we again restrict
the outcome only to men (column 5).
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B Compositional Effects
Figure B.1: Effects of CAPSs on dispensed antipsychotic drugs – 02-16
Average Treatment Effect:  12.91 (4.806)
Average Placebo Effect:  0.85 (0.340)
Baseline:  2.46
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered boot-strap
and dynamic and placebo DID estimators for the CAPSs’ effects on the rate of dispensed anti-psychotic drugs.
These are drugs delivered at the ambulatory level for patients, especially with schizophrenia and other psy-
chotic disorders, for home use. Here we restrict the treated sample to municipalities with at least five non-
missing post-CAPS data. The Average Treatment Effect and the Average Placebo Effect compute a simple
average of the non-placebo and placebo effects, respectively, considering the specification with state-specific
trends and controls. In parenthesis, standard errors computed with a municipality-level clustered bootstrap.
Baseline indicates the sample mean values for the treated in the pre-CAPS period.
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Figure B.2: Effects of CAPSs on hospitalization due to mental and behavioral disorders –
02-16
(a) Overall
Average Treatment Effect:  -0.96 (0.375)
Average Placebo Effect:  0.06 (0.106)
Baseline:  13.75
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(b) Long-stay (>30 days)
Average Treatment Effect:  -0.81 (0.145)
Average Placebo Effect:  0.05 (0.067)
Baseline:  6.76
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPSs’ effects on the rate of hospital admissions due to mental
and behavioral disorders (codes F00-F99). The same specifications from Figure 3 also apply here. Here we
restrict the treated sample to municipalities with at least five non-missing post-CAPS data. The Average Treat-
ment Effect and the Average Placebo Effect compute a simple average of the non-placebo and placebo effects,
respectively, considering the specification with state-specific trends and controls. In parenthesis, standard er-
rors computed with a municipality-level clustered bootstrap. Baseline indicates the sample mean values for
the treated in the pre-CAPS period.
80
Figure B.3: Effects of CAPSs on hospitalization due to mental and behavioral disorders by
cause – 02-16
(a) Schizophrenia
Average Treatment Effect:  -0.79 (0.159)
Average Placebo Effect:  0.07 (0.048)
Baseline:  6.12
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(b) Mood disorders
Average Treatment Effect:  -0.12 (0.095)
Average Placebo Effect:  0.02 (0.027)
Baseline:  1.71
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(c) Psychoactive substance abuse disorders
Average Treatment Effect:  0.10 (0.163)
Average Placebo Effect:  -0.04 (0.050)
Baseline:  4.40
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPSs’ effects on the rate of hospital admissions due to men-
tal and behavioral disorders by groups of cause: schizophrenia and related disorders (F20-F29), and mood
disorders (F30-F39). The same specifications from Figure 3 also apply here. Here we restrict the treated sam-
ple to municipalities with at least five non-missing post-CAPS data. The Average Treatment Effect and the
Average Placebo Effect compute a simple average of the non-placebo and placebo effects, respectively, con-
sidering the specification with state-specific trends and controls. In parenthesis, standard errors computed
with a municipality-level clustered bootstrap. Baseline indicates the sample mean values for the treated in the
pre-CAPS period.
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Figure B.4: Effects of CAPSs on homicides – 02-16
Average Treatment Effect:  0.13 (0.042)
Average Placebo Effect:  0.02 (0.016)
Baseline:  1.88
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPSs’ effects on the rate of homicide (X85-Y09). Here we restrict
the treated sample to municipalities with at least five non-missing post-CAPS data. The same specifications
from Figure 3 also apply here. The Average Treatment Effect and the Average Placebo Effect compute a simple
average of the non-placebo and placebo effects, respectively, considering the specification with state-specific
trends and controls. In parenthesis, standard errors computed with a municipality-level clustered bootstrap.
Baseline indicates the sample mean values for the treated in the pre-CAPS period.
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Figure B.5: Effects of CAPSs II on hospitalization due to mental and behavioral disorders –
02-16
(a) Overall
Average Treatment Effect:  -1.08 (0.496)
Average Placebo Effect:  -0.03 (0.148)
Baseline:  17.21
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(b) Long-stay (>30 days)
Average Treatment Effect:  -0.73 (0.240)
Average Placebo Effect:  0.07 (0.088)
Baseline:  8.09
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPS II effects on the rate of hospital admissions due to men-
tal and behavioral disorders by groups of cause: schizophrenia and related disorders (F20-F29), and mood
disorders (F30-F39). The same specifications from Figure 3 also apply here. Here we restrict the treated sam-
ple to municipalities with at least five non-missing post-CAPS data. The Average Treatment Effect and the
Average Placebo Effect compute a simple average of the non-placebo and placebo effects, respectively, con-
sidering the specification with state-specific trends and controls. In parenthesis, standard errors computed
with a municipality-level clustered bootstrap. Baseline indicates the sample mean values for the treated in the
pre-CAPS period.
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Figure B.6: Effects of CAPSs II on hospitalization due to mental and behavioral disorders by
cause – 02-16
(a) Schizophrenia
Average Treatment Effect:  -0.50 (0.179)
Average Placebo Effect:  0.01 (0.105)
Baseline:  7.12
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(b) Mood Disorders
Average Treatment Effect:  -0.40 (0.157)
Average Placebo Effect:  0.17 (0.086)
Baseline:  2.42
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(c) Psychoactive substance abuse disorders
Average Treatment Effect:  -0.10 (0.234)
Average Placebo Effect:  -0.22 (0.102)
Baseline:  5.86
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPS II effects on the rate of hospital admissions due to men-
tal and behavioral disorders by groups of cause: schizophrenia and related disorders (F20-F29), and mood
disorders (F30-F39). The same specifications from Figure 3 also apply here. Here we restrict the treated sam-
ple to municipalities with at least five non-missing post-CAPS data. The Average Treatment Effect and the
Average Placebo Effect compute a simple average of the non-placebo and placebo effects, respectively, con-
sidering the specification with state-specific trends and controls. In parenthesis, standard errors computed
with a municipality-level clustered bootstrap. Baseline indicates the sample mean values for the treated in the
pre-CAPS period.
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Figure B.7: Effects of CAPSs II on homicides – 02-16
Average Treatment Effect:  0.18 (0.081)
Average Placebo Effect:  -0.02 (0.027)
Baseline:  2.53
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPS II effects on the rate of homicide (X85-Y09). Here we restrict
the treated sample to municipalities with at least five non-missing post-CAPS data. The same specifications
from Figure 3 also apply here. The Average Treatment Effect and the Average Placebo Effect compute a simple
average of the non-placebo and placebo effects, respectively, considering the specification with state-specific
trends and controls. In parenthesis, standard errors computed with a municipality-level clustered bootstrap.
Baseline indicates the sample mean values for the treated in the pre-CAPS period.
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Figure B.8: Effects of CAPSs AD on hospitalization and mortality rates due to alcoholic liver
disease – 02-16
(a) Alcoholic liver disease
Average Treatment Effect:  -0.06 (0.022)
Average Placebo Effect:  0.01 (0.009)
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(b) Alcoholic and chronic liver disease
Average Treatment Effect:  -0.11 (0.029)
Average Placebo Effect:  -0.00 (0.014)
Baseline:  1.03
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPS AD effects on deaths due to alcoholic liver disease (panel
a; code K70) and alcoholic and unspecified sources of chronic liver diseases (panel b; code K70, K73, K74).
Here we use a restricted sample of municipalities with at least five non-missing post-CAPS data. The same
specifications from Figure 3 also apply here. We additionally control for the introduction of any other type of
center. The Average Treatment Effect and the Average Placebo Effect compute a simple average of the non-
placebo and placebo effects, respectively, considering the specification with state-specific trends and controls.
In parenthesis, standard errors computed with a municipality-level clustered bootstrap. Baseline indicates the
sample mean values for the treated in the pre-CAPS period.
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C Longer Event-Study
Figure C.1: Effects of CAPSs on hospitalization due to mental and behavioral disorders –
02-16
(a) Overall
Average Treatment Effect:  -0.74 (0.336)
Average Placebo Effect:  -0.02 (0.058)
Baseline:  12.61
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(b) Long-Stay (>30 days)
Average Treatment Effect:  -0.76 (0.238)
Average Placebo Effect:  -0.01 (0.035)
Baseline:  5.95
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPSs’ effects on the rate of hospital admissions due to mental
and behavioral disorders by groups of cause: schizophrenia and related disorders (F20-F29), mood disorders
(F30-F39), and psychoactive substance abuse disorders (F10-F19). Specifications include state-specific trends,
municipality GDP per capita (transformed by inverse hyerbolic sine), PBF speding per capita, and a series of
indicators for age-by-gender population bins. The Average Treatment Effect and the Average Placebo Effect
compute a simple average of the non-placebo and placebo effects, respectively, considering the specification
with state-specific trends and controls. In parenthesis, standard errors computed with a municipality-level
clustered bootstrap. Baseline indicates the sample mean values for the treated in the pre-CAPS period.
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Figure C.2: Effects of CAPSs on outpatient care by mental health specialists – 08-16
(a) Schizophrenia
Average Treatment Effect:  -0.61 (0.163)
Average Placebo Effect:  0.02 (0.027)
Baseline:  5.32
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(b) Mood disorders
Average Treatment Effect:  -0.12 (0.104)
Average Placebo Effect:  -0.00 (0.015)
Baseline:  1.64
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(c) Psychoactive substance abuse disorders
Average Treatment Effect:  0.13 (0.163)
Average Placebo Effect:  -0.00 (0.027)
Baseline:  4.29
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPSs’ effects on the rate of hospital admissions due to mental
and behavioral disorders by groups of cause: schizophrenia and related disorders (F20-F29), mood disorders
(F30-F39), and psychoactive substance abuse disorders (F10-F19). Specifications include state-specific trends,
municipality GDP per capita (transformed by inverse hyerbolic sine), PBF speding per capita, and a series of
indicators for age-by-gender population bins. The Average Treatment Effect and the Average Placebo Effect
compute a simple average of the non-placebo and placebo effects, respectively, considering the specification
with state-specific trends and controls. In parenthesis, standard errors computed with a municipality-level
clustered bootstrap. Baseline indicates the sample mean values for the treated in the pre-CAPS period.
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Figure C.3: Effects of CAPSs on homicides – 02-16
Average Treatment Effect:  0.17 (0.054)
Average Placebo Effect:  0.02 (0.008)
Baseline:  1.96
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPSs’ effects on the rate of homicide (X85-Y09). Here we restrict
the treated sample to municipalities with at least five non-missing post-CAPS data. The same specifications
from Figure 3 also apply here. The Average Treatment Effect and the Average Placebo Effect compute a simple
average of the non-placebo and placebo effects, respectively, considering the specification with state-specific
trends and controls. In parenthesis, standard errors computed with a municipality-level clustered bootstrap.
Baseline indicates the sample mean values for the treated in the pre-CAPS period.
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Figure C.4: Effects of CAPSs II on hospitalization due to mental and behavioral disorders –
02-16
(a) Overall
Average Treatment Effect:  -1.24 (0.558)
Average Placebo Effect:  -0.46 (0.217)
Baseline:  16.29
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(b) Long-stay (>30 days)
Average Treatment Effect:  -0.62 (0.313)
Average Placebo Effect:  -0.20 (0.167)
Baseline:  7.44
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPS II effects on the rate of hospital admissions due to mental
and behavioral disorders (F00-F99). The same specifications from Figure 3 also apply here. Here we restrict the
treated sample to municipalities with at least five non-missing post-CAPS data. The Average Treatment Effect
and the Average Placebo Effect compute a simple average of the non-placebo and placebo effects, respectively,
considering the specification with state-specific trends and controls. In parenthesis, standard errors computed
with a municipality-level clustered bootstrap. Baseline indicates the sample mean values for the treated in the
pre-CAPS period.
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Figure C.5: Effects of CAPSs II on outpatient care by mental health specialists – 08-16
(a) Schizophrenia
Average Treatment Effect:  -0.36 (0.260)
Average Placebo Effect:  -0.11 (0.099)
Baseline:  6.58
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(b) Mood Disorders
Average Treatment Effect:  -0.49 (0.180)
Average Placebo Effect:  0.07 (0.046)
Baseline:  2.39
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(c) Psychoactive substance abuse disorders
Average Treatment Effect:  -0.28 (0.283)
Average Placebo Effect:  -0.22 (0.067)
Baseline:  5.51
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPS II effects on the rate of hospital admissions due to men-
tal and behavioral disorders by groups of cause: schizophrenia and related disorders (F20-F29), and mood
disorders (F30-F39). The same specifications from Figure 3 also apply here. Here we restrict the treated sam-
ple to municipalities with at least five non-missing post-CAPS data. The Average Treatment Effect and the
Average Placebo Effect compute a simple average of the non-placebo and placebo effects, respectively, con-
sidering the specification with state-specific trends and controls. In parenthesis, standard errors computed
with a municipality-level clustered bootstrap. Baseline indicates the sample mean values for the treated in the
pre-CAPS period.
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Figure C.6: Effects of CAPSs II on homicides – 02-16
Average Treatment Effect:  0.20 (0.093)
Average Placebo Effect:  -0.02 (0.023)
Baseline:  2.53
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPS II effects on the rate of homicide (X85-Y09). Here we restrict
the treated sample to municipalities with at least five non-missing post-CAPS data. The same specifications
from Figure 3 also apply here. The Average Treatment Effect and the Average Placebo Effect compute a simple
average of the non-placebo and placebo effects, respectively, considering the specification with state-specific
trends and controls. In parenthesis, standard errors computed with a municipality-level clustered bootstrap.
Baseline indicates the sample mean values for the treated in the pre-CAPS period.
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Figure C.7: Effects of CAPSs AD on mortality rates due to alcoholic liver disease – 02-16
(a) Alcoholic liver disease
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Average Placebo Effect:  -0.01 (0.007)
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(b) Alcoholic and chronic liver disease
Average Treatment Effect:  -0.12 (0.028)
Average Placebo Effect:  -0.00 (0.009)
Baseline:  1.07
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Notes: This figure plots 95% confidence-intervals computed with a municipality-level clustered bootstrap and
dynamic and placebo DID estimators for the CAPS AD effects on deaths due to alcoholic liver disease (panel
a; code K70) and alcoholic and unspecified sources of chronic liver diseases (panel b; code K70, K73, K74).
Here we use a restricted sample of municipalities with at least five non-missing post-CAPS data. The same
specifications from Figure 3 also apply here. We additionally control for the introduction of any other type of
center. The Average Treatment Effect and the Average Placebo Effect compute a simple average of the non-
placebo and placebo effects, respectively, considering the specification with state-specific trends and controls.
In parenthesis, standard errors computed with a municipality-level clustered bootstrap. Baseline indicates the
sample mean values for the treated in the pre-CAPS period.
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